KR101068128B1 - Natural product composition containing ionized calcium fertilized unmilled rice for activating alcohol excretion,aldehyde metabolism and curing a hangover and preparation method thereof - Google Patents
Natural product composition containing ionized calcium fertilized unmilled rice for activating alcohol excretion,aldehyde metabolism and curing a hangover and preparation method thereof Download PDFInfo
- Publication number
- KR101068128B1 KR101068128B1 KR1020080109116A KR20080109116A KR101068128B1 KR 101068128 B1 KR101068128 B1 KR 101068128B1 KR 1020080109116 A KR1020080109116 A KR 1020080109116A KR 20080109116 A KR20080109116 A KR 20080109116A KR 101068128 B1 KR101068128 B1 KR 101068128B1
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- parts
- calcium
- alcohol
- extract
- Prior art date
Links
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title claims abstract description 171
- 239000000203 mixture Substances 0.000 title claims abstract description 100
- 206010019133 Hangover Diseases 0.000 title claims abstract description 65
- 239000011575 calcium Substances 0.000 title claims abstract description 52
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title claims abstract description 51
- 229910052791 calcium Inorganic materials 0.000 title claims abstract description 51
- 230000029142 excretion Effects 0.000 title claims abstract description 22
- 230000004060 metabolic process Effects 0.000 title claims description 31
- 238000002360 preparation method Methods 0.000 title description 9
- 230000003213 activating effect Effects 0.000 title description 5
- 229930014626 natural product Natural products 0.000 title description 3
- 240000007594 Oryza sativa Species 0.000 title description 2
- 235000007164 Oryza sativa Nutrition 0.000 title description 2
- 235000009566 rice Nutrition 0.000 title description 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 title 1
- 239000000284 extract Substances 0.000 claims abstract description 64
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 30
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims abstract description 26
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 26
- 235000021329 brown rice Nutrition 0.000 claims abstract description 24
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 24
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 23
- 244000068988 Glycine max Species 0.000 claims abstract description 23
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 22
- 239000008103 glucose Substances 0.000 claims abstract description 21
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 20
- 238000004519 manufacturing process Methods 0.000 claims abstract description 19
- 240000004922 Vigna radiata Species 0.000 claims abstract description 18
- 235000010721 Vigna radiata var radiata Nutrition 0.000 claims abstract description 18
- 229940043430 calcium compound Drugs 0.000 claims abstract description 17
- 150000001674 calcium compounds Chemical class 0.000 claims abstract description 17
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims abstract description 17
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims abstract description 16
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims abstract description 16
- 239000011976 maleic acid Substances 0.000 claims abstract description 16
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 claims abstract description 15
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims abstract description 14
- 244000046052 Phaseolus vulgaris Species 0.000 claims abstract description 14
- 210000004207 dermis Anatomy 0.000 claims abstract description 14
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 claims abstract description 13
- 229960003237 betaine Drugs 0.000 claims abstract description 13
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 claims abstract description 13
- 229940114124 ferulic acid Drugs 0.000 claims abstract description 13
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 claims abstract description 13
- 235000001785 ferulic acid Nutrition 0.000 claims abstract description 13
- 229960003080 taurine Drugs 0.000 claims abstract description 13
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 claims abstract description 13
- 241001107116 Castanospermum australe Species 0.000 claims abstract description 12
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical group [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 claims abstract description 12
- 235000021279 black bean Nutrition 0.000 claims abstract description 12
- 239000004310 lactic acid Substances 0.000 claims abstract description 12
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 12
- 150000003839 salts Chemical class 0.000 claims abstract description 12
- 240000001417 Vigna umbellata Species 0.000 claims abstract description 11
- 235000011453 Vigna umbellata Nutrition 0.000 claims abstract description 11
- 240000004670 Glycyrrhiza echinata Species 0.000 claims abstract description 10
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims abstract description 10
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 10
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims abstract description 10
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 claims abstract description 10
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 10
- 244000273928 Zingiber officinale Species 0.000 claims abstract description 10
- 235000008397 ginger Nutrition 0.000 claims abstract description 10
- 229940010454 licorice Drugs 0.000 claims abstract description 10
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- 241000218206 Ranunculus Species 0.000 claims abstract description 6
- 239000002904 solvent Substances 0.000 claims abstract description 5
- 241000266501 Ormosia ormondii Species 0.000 claims abstract description 4
- 244000126002 Ziziphus vulgaris Species 0.000 claims abstract description 4
- 244000088415 Raphanus sativus Species 0.000 claims abstract 3
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims description 54
- 229960005069 calcium Drugs 0.000 claims description 48
- 238000000034 method Methods 0.000 claims description 20
- 230000002829 reductive effect Effects 0.000 claims description 17
- 230000001737 promoting effect Effects 0.000 claims description 13
- 238000000605 extraction Methods 0.000 claims description 10
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 8
- 229910001424 calcium ion Inorganic materials 0.000 claims description 8
- 235000013305 food Nutrition 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 7
- 241000195955 Equisetum hyemale Species 0.000 claims description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 4
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 4
- 241001474374 Blennius Species 0.000 claims description 4
- 239000005862 Whey Substances 0.000 claims description 4
- 102000007544 Whey Proteins Human genes 0.000 claims description 4
- 108010046377 Whey Proteins Proteins 0.000 claims description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 4
- 159000000007 calcium salts Chemical class 0.000 claims description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 4
- 239000011701 zinc Substances 0.000 claims description 4
- 241000218201 Ranunculaceae Species 0.000 claims description 3
- 229910052742 iron Inorganic materials 0.000 claims description 3
- 239000011777 magnesium Substances 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 229910052725 zinc Inorganic materials 0.000 claims description 3
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 2
- 235000020958 biotin Nutrition 0.000 claims description 2
- 239000011616 biotin Substances 0.000 claims description 2
- 229960002685 biotin Drugs 0.000 claims description 2
- 229940041514 candida albicans extract Drugs 0.000 claims description 2
- 229960000304 folic acid Drugs 0.000 claims description 2
- 239000011724 folic acid Substances 0.000 claims description 2
- 235000019152 folic acid Nutrition 0.000 claims description 2
- 229960003284 iron Drugs 0.000 claims description 2
- 229940091250 magnesium supplement Drugs 0.000 claims description 2
- 229940055726 pantothenic acid Drugs 0.000 claims description 2
- 235000019161 pantothenic acid Nutrition 0.000 claims description 2
- 239000011713 pantothenic acid Substances 0.000 claims description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 2
- 239000012138 yeast extract Substances 0.000 claims description 2
- 235000016804 zinc Nutrition 0.000 claims description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 2
- 240000004160 Capsicum annuum Species 0.000 claims 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 claims 1
- 235000007862 Capsicum baccatum Nutrition 0.000 claims 1
- 239000001728 capsicum frutescens Substances 0.000 claims 1
- 235000005152 nicotinamide Nutrition 0.000 claims 1
- 239000011570 nicotinamide Substances 0.000 claims 1
- 238000000354 decomposition reaction Methods 0.000 abstract description 5
- 150000001875 compounds Chemical class 0.000 abstract description 4
- 235000011330 Armoracia rusticana Nutrition 0.000 abstract description 3
- 240000003291 Armoracia rusticana Species 0.000 abstract description 3
- 239000002075 main ingredient Substances 0.000 abstract description 2
- 235000019441 ethanol Nutrition 0.000 description 127
- 235000001465 calcium Nutrition 0.000 description 36
- 230000000694 effects Effects 0.000 description 33
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 30
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 30
- 230000035622 drinking Effects 0.000 description 24
- 239000008280 blood Substances 0.000 description 19
- 210000004369 blood Anatomy 0.000 description 19
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 19
- 238000010521 absorption reaction Methods 0.000 description 16
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 15
- 229950006238 nadide Drugs 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 239000012153 distilled water Substances 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 235000013399 edible fruits Nutrition 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 241000220259 Raphanus Species 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- -1 Cu-Zn peroxide Chemical class 0.000 description 6
- 208000004930 Fatty Liver Diseases 0.000 description 6
- 206010019708 Hepatic steatosis Diseases 0.000 description 6
- 240000008866 Ziziphus nummularia Species 0.000 description 6
- 229940003871 calcium ion Drugs 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 208000010706 fatty liver disease Diseases 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 231100000240 steatosis hepatitis Toxicity 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 238000001784 detoxification Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 241000411851 herbal medicine Species 0.000 description 5
- 235000008216 herbs Nutrition 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 230000003908 liver function Effects 0.000 description 5
- 238000006241 metabolic reaction Methods 0.000 description 5
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 230000019525 primary metabolic process Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 206010028813 Nausea Diseases 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 description 4
- 239000000378 calcium silicate Substances 0.000 description 4
- 229910052918 calcium silicate Inorganic materials 0.000 description 4
- 235000012241 calcium silicate Nutrition 0.000 description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 4
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000001882 diuretic effect Effects 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 235000021374 legumes Nutrition 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 230000008693 nausea Effects 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000003440 toxic substance Substances 0.000 description 4
- 208000007848 Alcoholism Diseases 0.000 description 3
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 3
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 3
- UNMYWSMUMWPJLR-UHFFFAOYSA-L Calcium iodide Chemical compound [Ca+2].[I-].[I-] UNMYWSMUMWPJLR-UHFFFAOYSA-L 0.000 description 3
- 229910017518 Cu Zn Inorganic materials 0.000 description 3
- 229910017752 Cu-Zn Inorganic materials 0.000 description 3
- 229910017943 Cu—Zn Inorganic materials 0.000 description 3
- 206010023126 Jaundice Diseases 0.000 description 3
- 206010067125 Liver injury Diseases 0.000 description 3
- 240000004371 Panax ginseng Species 0.000 description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 description 3
- 244000046146 Pueraria lobata Species 0.000 description 3
- 235000010575 Pueraria lobata Nutrition 0.000 description 3
- 244000299790 Rheum rhabarbarum Species 0.000 description 3
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 201000007930 alcohol dependence Diseases 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 229940046413 calcium iodide Drugs 0.000 description 3
- 229910001640 calcium iodide Inorganic materials 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- GBAOBIBJACZTNA-UHFFFAOYSA-L calcium sulfite Chemical compound [Ca+2].[O-]S([O-])=O GBAOBIBJACZTNA-UHFFFAOYSA-L 0.000 description 3
- 235000010261 calcium sulphite Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003337 fertilizer Substances 0.000 description 3
- 235000008434 ginseng Nutrition 0.000 description 3
- 230000034659 glycolysis Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000037353 metabolic pathway Effects 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 231100000167 toxic agent Toxicity 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- XMGQYMWWDOXHJM-JTQLQIEISA-N (+)-α-limonene Chemical compound CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 description 2
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 2
- LXJXRIRHZLFYRP-VKHMYHEASA-L (R)-2-Hydroxy-3-(phosphonooxy)-propanal Natural products O=C[C@H](O)COP([O-])([O-])=O LXJXRIRHZLFYRP-VKHMYHEASA-L 0.000 description 2
- YEDFEBOUHSBQBT-UHFFFAOYSA-N 2,3-dihydroflavon-3-ol Chemical compound O1C2=CC=CC=C2C(=O)C(O)C1C1=CC=CC=C1 YEDFEBOUHSBQBT-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 239000004151 Calcium iodate Substances 0.000 description 2
- 235000001543 Corylus americana Nutrition 0.000 description 2
- 235000007466 Corylus avellana Nutrition 0.000 description 2
- 240000007582 Corylus avellana Species 0.000 description 2
- GSXOAOHZAIYLCY-UHFFFAOYSA-N D-F6P Natural products OCC(=O)C(O)C(O)C(O)COP(O)(O)=O GSXOAOHZAIYLCY-UHFFFAOYSA-N 0.000 description 2
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 2
- LXJXRIRHZLFYRP-VKHMYHEASA-N D-glyceraldehyde 3-phosphate Chemical compound O=C[C@H](O)COP(O)(O)=O LXJXRIRHZLFYRP-VKHMYHEASA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000220485 Fabaceae Species 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 231100000111 LD50 Toxicity 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- BGWGXPAPYGQALX-ARQDHWQXSA-N beta-D-fructofuranose 6-phosphate Chemical compound OC[C@@]1(O)O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O BGWGXPAPYGQALX-ARQDHWQXSA-N 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000006931 brain damage Effects 0.000 description 2
- 231100000874 brain damage Toxicity 0.000 description 2
- 208000029028 brain injury Diseases 0.000 description 2
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 2
- 239000001639 calcium acetate Substances 0.000 description 2
- 235000011092 calcium acetate Nutrition 0.000 description 2
- 229960005147 calcium acetate Drugs 0.000 description 2
- 239000011692 calcium ascorbate Substances 0.000 description 2
- 235000010376 calcium ascorbate Nutrition 0.000 description 2
- 229940047036 calcium ascorbate Drugs 0.000 description 2
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 2
- 239000004227 calcium gluconate Substances 0.000 description 2
- 229960004494 calcium gluconate Drugs 0.000 description 2
- 235000013927 calcium gluconate Nutrition 0.000 description 2
- UHWJJLGTKIWIJO-UHFFFAOYSA-L calcium iodate Chemical compound [Ca+2].[O-]I(=O)=O.[O-]I(=O)=O UHWJJLGTKIWIJO-UHFFFAOYSA-L 0.000 description 2
- 235000019390 calcium iodate Nutrition 0.000 description 2
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 description 2
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 2
- 239000000292 calcium oxide Substances 0.000 description 2
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 2
- 235000012255 calcium oxide Nutrition 0.000 description 2
- 229940043256 calcium pyrophosphate Drugs 0.000 description 2
- 235000011132 calcium sulphate Nutrition 0.000 description 2
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 description 2
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- TVZPLCNGKSPOJA-UHFFFAOYSA-N copper zinc Chemical compound [Cu].[Zn] TVZPLCNGKSPOJA-UHFFFAOYSA-N 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 2
- 244000013123 dwarf bean Species 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- RNBGYGVWRKECFJ-UHFFFAOYSA-N fructose-1,6-phosphate Natural products OC1C(O)C(O)(COP(O)(O)=O)OC1COP(O)(O)=O RNBGYGVWRKECFJ-UHFFFAOYSA-N 0.000 description 2
- 208000001130 gallstones Diseases 0.000 description 2
- 230000004153 glucose metabolism Effects 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 229930013032 isoflavonoid Natural products 0.000 description 2
- 150000003817 isoflavonoid derivatives Chemical class 0.000 description 2
- 235000012891 isoflavonoids Nutrition 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 108010033145 microsomal ethanol-oxidizing system Proteins 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 150000003248 quinolines Chemical class 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- YRCWQPVGYLYSOX-UHFFFAOYSA-N synephrine Chemical compound CNCC(O)C1=CC=C(O)C=C1 YRCWQPVGYLYSOX-UHFFFAOYSA-N 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- OCUSNPIJIZCRSZ-ZTZWCFDHSA-N (2s)-2-amino-3-methylbutanoic acid;(2s)-2-amino-4-methylpentanoic acid;(2s,3s)-2-amino-3-methylpentanoic acid Chemical compound CC(C)[C@H](N)C(O)=O.CC[C@H](C)[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O OCUSNPIJIZCRSZ-ZTZWCFDHSA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- CDDWAYFUFNQLRZ-KJVHGCRFSA-N (3beta,21beta,22beta)-olean-12-ene-3,21,22,24-tetrol Chemical compound C([C@@]12C)C[C@H](O)[C@](C)(CO)[C@@H]1CC[C@]1(C)[C@@H]2CC=C2[C@@H]3CC(C)(C)[C@@H](O)[C@@H](O)[C@]3(C)CC[C@]21C CDDWAYFUFNQLRZ-KJVHGCRFSA-N 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UYBWIEGTWASWSR-UHFFFAOYSA-N 1,3-diaminopropan-2-ol Chemical compound NCC(O)CN UYBWIEGTWASWSR-UHFFFAOYSA-N 0.000 description 1
- OHXPGWPVLFPUSM-KLRNGDHRSA-N 3,7,12-trioxo-5beta-cholanic acid Chemical compound C1CC(=O)C[C@H]2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC(O)=O)C)[C@@]4(C)C(=O)C[C@@H]3[C@]21C OHXPGWPVLFPUSM-KLRNGDHRSA-N 0.000 description 1
- LJQLQCAXBUHEAZ-UWTATZPHSA-N 3-phospho-D-glyceroyl dihydrogen phosphate Chemical compound OP(=O)(O)OC[C@@H](O)C(=O)OP(O)(O)=O LJQLQCAXBUHEAZ-UWTATZPHSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 108091023020 Aldehyde Oxidase Proteins 0.000 description 1
- 102000048262 Aldehyde oxidases Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 240000000724 Berberis vulgaris Species 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 206010048909 Boredom Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 235000014653 Carica parviflora Nutrition 0.000 description 1
- 244000132059 Carica parviflora Species 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 241000675108 Citrus tangerina Species 0.000 description 1
- 241000555678 Citrus unshiu Species 0.000 description 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 1
- 235000009685 Crataegus X maligna Nutrition 0.000 description 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 1
- 235000009486 Crataegus bullatus Nutrition 0.000 description 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 1
- 235000009682 Crataegus limnophila Nutrition 0.000 description 1
- 240000000171 Crataegus monogyna Species 0.000 description 1
- 235000004423 Crataegus monogyna Nutrition 0.000 description 1
- 235000002313 Crataegus paludosa Nutrition 0.000 description 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- XPYBSIWDXQFNMH-UHFFFAOYSA-N D-fructose 1,6-bisphosphate Natural products OP(=O)(O)OCC(O)C(O)C(O)C(=O)COP(O)(O)=O XPYBSIWDXQFNMH-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N Daidzein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 1
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 description 1
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000195952 Equisetaceae Species 0.000 description 1
- 244000085625 Equisetum Species 0.000 description 1
- 241000195950 Equisetum arvense Species 0.000 description 1
- 239000005768 Equisetum arvense L. Substances 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 108010063907 Glutathione Reductase Proteins 0.000 description 1
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- 241000405398 Hovenia Species 0.000 description 1
- 235000008586 Hovenia Nutrition 0.000 description 1
- ARFZEJYVBXGWDN-YPKPFQOOSA-N Hovenine A Chemical compound C/1=C/NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(NC)C(C)CC)C(C(C)C)OC2=CC=C\1C=C2 ARFZEJYVBXGWDN-YPKPFQOOSA-N 0.000 description 1
- PPJRLNYZNPESCY-UHFFFAOYSA-N Hovenine A Natural products CCCC(C)C(N)C(=O)NC1C(Oc2ccc(C=C/NC(=O)C(CC(C)C)NC1=O)cc2)C(C)C PPJRLNYZNPESCY-UHFFFAOYSA-N 0.000 description 1
- NICHEDAQBKUSBN-XNHBMLHPSA-N Hovenolactone Chemical compound CC(C)=C[C@H](O)C[C@]1(C)O[C@H]1[C@@H]1[C@@]2(CC(=O)OC2)[C@]2(C)CCC3C(C)(C)[C@@H](O)CC[C@]3(C)C2CC1 NICHEDAQBKUSBN-XNHBMLHPSA-N 0.000 description 1
- NICHEDAQBKUSBN-UHFFFAOYSA-N Hovenolactone Natural products CC(=CC(O)CC1(C)OC1C2CCC3C4(C)CCC(O)C(C)(C)C4CCC3(C)C25COC(=O)C5)C NICHEDAQBKUSBN-UHFFFAOYSA-N 0.000 description 1
- QZYVSOVGZWRNEK-UHFFFAOYSA-N Hovenoside D Natural products CC(=CC1CC(C)(O)C2C3CCC4C5(C)CCC(OC6OCC(O)C(OC7OC(COC8OC(CO)C(O)C(O)C8OC9OCC(O)C(O)C9O)C(O)C(O)C7O)C6OC%10OCC(O)C(O)C%10O)C(C)(C)C5CCC4(C)C3%11COC2(C%11)O1)C QZYVSOVGZWRNEK-UHFFFAOYSA-N 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000361919 Metaphire sieboldi Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- ARFZEJYVBXGWDN-UHFFFAOYSA-N N-demethyl-frangulanine Natural products C1=CNC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(NC)C(C)CC)C(C(C)C)OC2=CC=C1C=C2 ARFZEJYVBXGWDN-UHFFFAOYSA-N 0.000 description 1
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 description 1
- 108010053775 Nisin Proteins 0.000 description 1
- OBIOZWXPDBWYHB-UHFFFAOYSA-N Nobiletin Natural products C1=CC(OC)=CC=C1C1=C(OC)C(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 OBIOZWXPDBWYHB-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000237503 Pectinidae Species 0.000 description 1
- 244000062780 Petroselinum sativum Species 0.000 description 1
- 235000006089 Phaseolus angularis Nutrition 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 235000009984 Pterocarpus indicus Nutrition 0.000 description 1
- 244000086363 Pterocarpus indicus Species 0.000 description 1
- 241000206572 Rhodophyta Species 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- BHTRKEVKTKCXOH-UHFFFAOYSA-N Taurochenodesoxycholsaeure Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)CC2 BHTRKEVKTKCXOH-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 240000007098 Vigna angularis Species 0.000 description 1
- 235000010716 Vigna mungo Nutrition 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229940100228 acetyl coenzyme a Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- RNBGYGVWRKECFJ-ZXXMMSQZSA-N alpha-D-fructofuranose 1,6-bisphosphate Chemical compound O[C@H]1[C@H](O)[C@](O)(COP(O)(O)=O)O[C@@H]1COP(O)(O)=O RNBGYGVWRKECFJ-ZXXMMSQZSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 1
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 description 1
- 229960002997 dehydrocholic acid Drugs 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000004262 dental pulp cavity Anatomy 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960002563 disulfiram Drugs 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000007937 eating Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 230000004149 ethanol metabolism Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 230000037341 glyoxalate cycle Effects 0.000 description 1
- 235000021331 green beans Nutrition 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- DPMKYRJUMRDZSZ-UHFFFAOYSA-N hoduloside I Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C3C(C4C(C5(CC(=O)OC5)C(C5C(O5)(C)CC(OC5C(C(O)C(O)C(CO)O5)O)C=C(C)C)CC4)(C)CC3)(C)CC2)(C)C)OC(CO)C(O)C1O DPMKYRJUMRDZSZ-UHFFFAOYSA-N 0.000 description 1
- WLTXBTSNYDYARD-UHFFFAOYSA-N hoduloside III Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(O)COC1OC1C(C)(C)C(CCC2(C)C34CC5(C(C(CC(O5)C=C(C)C)(C)O)C4CCC42)OC3)C4(C)CC1 WLTXBTSNYDYARD-UHFFFAOYSA-N 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 235000019707 mung bean protein Nutrition 0.000 description 1
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 description 1
- 229940052490 naringin Drugs 0.000 description 1
- 229930019673 naringin Natural products 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
- 229940101270 nicotinamide adenine dinucleotide (nad) Drugs 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000010297 nisin Nutrition 0.000 description 1
- 239000004309 nisin Substances 0.000 description 1
- 229910017464 nitrogen compound Inorganic materials 0.000 description 1
- 150000002830 nitrogen compounds Chemical class 0.000 description 1
- MRIAQLRQZPPODS-UHFFFAOYSA-N nobiletin Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 MRIAQLRQZPPODS-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229960003684 oxedrine Drugs 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 150000002927 oxygen compounds Chemical class 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000011197 perejil Nutrition 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000021445 popular drink Nutrition 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 235000020637 scallop Nutrition 0.000 description 1
- 230000024053 secondary metabolic process Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 235000019997 soju Nutrition 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- CDDWAYFUFNQLRZ-UHFFFAOYSA-N soyasapogenol A Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)C(O)C(O)C3(C)CCC21C CDDWAYFUFNQLRZ-UHFFFAOYSA-N 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- BHTRKEVKTKCXOH-LBSADWJPSA-N tauroursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)CC1 BHTRKEVKTKCXOH-LBSADWJPSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 1
- 229960001661 ursodiol Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/334—Foods, ingredients or supplements having a functional effect on health treating the effects of consuming alcohol, narcotics or other addictive behavior, e.g. treating hangover or reducing blood alcohol levels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Botany (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 활성 성분으로서 이온화칼슘 시비 현미를 주성분으로 하고 여기에 쇠뜨기, 흑두, 녹두, 적소두, 지구자, 갈근, 감초, 진피, 대추, 갈화, 미나리, 무우, 콩나물(대두 황권), 생강, 칼슘 화합물을 알코올이나 열수를 용매로서 이용하여 추출하고, 상기 추출물에 설탕 또는 포도당과, 말레인산, 젖산 또는 그 염, 페룰산, 타우린, 베타인을 용해시킨 알코올 배설 및 아세트알데히드 분해 촉진과 숙취(hang-over) 해소에 있어서 우수한 효과를 갖는 숙취 해소용 조성물 및 이의 제조 방법에 관한 것이다. In the present invention, as an active ingredient, the main ingredient is calcium ionized brown rice, which is made of horseradish, black bean, mung bean, red bean sprout, earth flakes, brown root, licorice, dermis, jujube, brownish, buttercup, radish, bean sprouts (soybean yellow beans), ginger, calcium The compound is extracted using alcohol or hot water as a solvent, alcohol excretion and hang-over decomposition of acetaldehyde, in which sugar or glucose, maleic acid, lactic acid or its salt, ferulic acid, taurine, and betaine are dissolved in the extract. The present invention relates to a hangover-relieving composition and a method for producing the same.
칼슘화합물, 숙취, 아세트알데히드, 설탕, 포도당 Calcium Compounds, Hangovers, Acetaldehyde, Sugar, Glucose
Description
본 발명은 알코올 배설 및 아세트알데히드 분해 촉진과 숙취(hang-over) 해소에 있어서 우수한 효과를 갖는 숙취 해소용 조성물 및 이의 제조 방법에 관한 것이다. The present invention relates to a hangover-relieving composition and a method for producing the same having excellent effects in promoting alcohol excretion, acetaldehyde decomposition and hang-over.
국내에서 최대로 애용되는 음료인 술은, 과량 섭취하게 되는 경우 개인적으로 정신적인 면 또는 육체적인 면에서, 사회적으로도 각종 문제를 야기하게 되는데, 음주에 의해 흡수된 알코올의 약 10%는 호흡이나 소변을 통해 체외로 배출되고, 나머지 90%의 대부분은 위 점막이나 간에서 대사되게 된다. 알코올 대사는 주로 간에서 일어나며 Zn을 함유한 ADH(Alcohol Dehydrogenase)에 의하여 아세트알데히드(acetaldehyde)로 대사되며, 이러한 과정은 NAD(Nicotinamide Adenine dinucleotide)를 필요로 한다. ADH에 의한 반응은 영차 반응 속도식(zero order kinetics)에 의하여 이루어지며 그 반응 속도는 일정하다. 아세트알데히드는 알코올 탈수소효소(Aldehyde dehydrogenase, ALDH)에 의하여 초산(acetic acid)으로 변화되며, 이 과정에서도 NAD가 필요하다 (조재열 등, 한국식품과학회지, 29(1), 167-172(1997)). 이 반응은 충분한 양의 ALDH 가 생성되어 있을 경우는 대단히 빨라서, 대량의 알코올을 섭취하더라도 혈중 아세트알데히드의 농도는 극히 낮다. Drinking alcohol, which is the most popular drink in Korea, causes excessive social problems, both personally and mentally and physically. When about 10% of alcohol absorbed by drinking It is excreted through the urine and most of the remaining 90% is metabolized in the gastric mucosa or liver. Alcohol metabolism occurs mainly in the liver and is metabolized to acetaldehyde by Zn-containing alcohol dehydrogenase (ADH), which requires nicotinamide adenine dinucleotide (NAD). The reaction by ADH is achieved by zero order kinetics and the reaction rate is constant. Acetaldehyde is converted to acetic acid by alcohol dehydrogenase (ALDH), and NAD is also required in this process (Jae-Yeol Cho , 29 (1), 167-172 (1997) ). This reaction is very fast when a sufficient amount of ALDH is produced, and the concentration of acetaldehyde in the blood is extremely low even when a large amount of alcohol is ingested.
그러나 충분한 양의 ALDH 가 생성되기 전, 특히 음주 초기는 이 반응이 매우 느리게 일어나 아세트알데히드가 축적되어 숙취를 일으킨다. However, before a sufficient amount of ALDH is produced, especially in the early stages of drinking, the reaction is very slow, acetaldehyde accumulates and causes a hangover.
생성된 아세테이트는 다시 아세틸 코엔자임 A(acetyl Coenzyme A)로 변환되어, TCA(tricarboxylic acid cycle)을 거쳐서 CO2 와 H2O로 산화된다 (조재열 등; Lieber C.S. 및 Leo M.A., In Progress in liver diseases, Popper, H. 및 Schaffner, F. (Ed), Grune amd Stration, New York, p.253(1986); 및 Linder M.C.). The resulting acetate is again converted to acetyl Coenzyme A and oxidized to CO 2 and H 2 O via a tricarboxylic acid cycle (Cho Jae-Hyeol et al .; Lieber CS and Leo MA, In Progress in liver diseases, Popper, H. and Schaffner, F. (Ed), Grune amd Stration, New York, p.253 (1986); and Linder MC).
만성적인 에탄올 섭취가 고지혈증 및 지방간을 유발 기전과 관련하여, 알코올탈수소효소 (ADH)와 알데히드탈수소효소(ALDH)에 의한 에탄올의 대사 결과 간과 세포내 NADH/NAD+ 비율을 증가시키게 되고, 이와 같은 변화는 간세포 내에서 지방산의 산화와 TCA 사이클 활성을 증가시켜, 지방간을 초래하게 된다는 이론이 있다 (Murray R.K. 등, Haper's Biochemistry, Appleton & Lange, Connechcut, USA. 3rd ed, p260 (1993)). Chronic ethanol uptake causes hyperlipidemia and fatty liver, leading to increased liver and intracellular NADH / NAD + ratios as a result of ethanol metabolism by alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH). Theorem has been shown to increase fatty acid oxidation and TCA cycle activity in hepatocytes, resulting in fatty liver (Murray RK et al., Haper's Biochemistry, Appleton & Lange, Connechcut, USA. 3rd ed, p260 (1993)).
숙취에 있어서, 알코올 음용으로 생성되는 아세트알데히드가 주요 독성 물질 로 작용하며, 알코올 대사 과정에서 활성 산소가 다량으로 발생하여 이들이 알코올성 장애를 초래하는 주요 원인이 된다. In hangovers, acetaldehyde produced by alcohol consumption acts as a major toxic substance, and a large amount of free radicals are generated in alcohol metabolism process, which is the main cause of alcoholic disorders.
생체 내에서는 음주 후 빠른 속도로 아세트알데히드를 분해하기 위하여 알데히드 탈수소효소(aldehyde dehydrogenase, 이하 ALDH라고 함)를 비롯한 다양한 효소들이 참여하여 아세트알데히드의 분해를 촉진시킨다(Lieber, C.S. : Hepatology, 4: 1243-1260, 1984). 알코올 중독증 환자의 치료법 중 ALDH 저해제인 디설피람(disulfiram)의 투여 방법이 있는데, 이것은 혈중에 고농도의 아세트알데히드를 농축시켜 환자가 알코올을 섭취하였을 때 강한 불쾌감, 메스꺼움을 느끼게 하여 알코올 섭취를 막아주는 방법이다. 특히, 이 과정에서 불쾌감과 메스꺼움은 숙취 증상과 유사하여 아세트알데히드에 의해 숙취가 발생한다고 보게 되었다(Gessa G.L. Guidelines for the drug therapy of alcoholism Recenti Prog Med 1990 Mar ; 81(3) : 171-5). In vivo, a variety of enzymes, including aldehyde dehydrogenase (ALDH), participate in the rapid degradation of acetaldehyde after drinking alcohol (Lieber, CS: Hepatology, 4: 1243). -1260, 1984). One of the treatment methods for alcoholism is the administration of disulfiram, an ALDH inhibitor, which concentrates high concentrations of acetaldehyde in the blood so that the patient feels strong discomfort and nausea when they ingest alcohol. Way. In particular, discomfort and nausea are similar to hangover symptoms, and it is considered that hangover is caused by acetaldehyde (Gessa GL Guidelines for the drug therapy of alcoholism Recenti Prog Med 1990 Mar; 81 (3): 171-5).
특히, 에탄올은 체내에서 아세트알데히드로 처음 분해된 후 초산으로 분해되는데, 고농도의 활성 화합물인 아세트알데히드는 발한(sweat), 급맥(rapid pulse), 피부 발열(skin flushing), 오심(nausea) 및 구토(vomiting)를 유발할 수 있다 (Rosser B.G. 및 Gores G.J., Gastroenterology, 108, 252(1995)). 이러한 이유로 현대 대부분의 연구자들은 알코올 분해산물인 아세트알데히드가 숙취의 원인이라고 생각하고 있다. Sherif, S., Wahlstrom, G., Oreland, L. Alcohol, Clin. Exp. Res. 17(6):1313-1318, 1993). In particular, ethanol is first decomposed into acetaldehyde in the body and then to acetic acid. Acetaldehyde, a high concentration of active compound, is sweat, rapid pulse, skin flushing, nausea and vomiting. may cause vomiting (Rosser BG and Gores GJ, Gastroenterology, 108, 252 (1995)). For this reason, most modern researchers believe that acetaldehyde, the alcohol breakdown product, is the cause of hangovers. Sherif, S., Wahlstrom, G., Oreland, L. Alcohol, Clin. Exp. Res. 17 (6): 1313-1318, 1993).
숙취의 경험은 매우 개인적인 성향과 상황 및 소비된 알코올의 종류와 양에 의존적이다. 신체적 숙취 증상들은 두통, 피로, 빛과 소리 민감성, 근육통, 안구 충혈, 갈증, 오심, 구토 및 위통을 동반한다. 숙취는 빠른 심장 박동, 흥분, 혈압 상승 및 발한의 원인이 되기도 한다. 숙취와 관련된 정신적 증상들로는 수면 부족, 수면장소 변화, 주의력 감소, 집중력 저하, 우울, 현기증, 불안, 과민 등이 있다. The hangover experience is very dependent on personal preferences and circumstances and the type and amount of alcohol consumed. Physical hangover symptoms are accompanied by headaches, fatigue, light and sound sensitivity, myalgia, hyperemia, thirst, nausea, vomiting and stomach pain. Hangovers can also cause rapid heartbeat, excitement, increased blood pressure and sweating. Mental symptoms associated with a hangover include sleep deprivation, changes in sleeping places, decreased attention, decreased concentration, depression, dizziness, anxiety, and irritability.
이러한 유해 현상은 아세트알데히드의 생성 시에 발생하는 과산화 반응과 MEOS의 촉매에 의해 형성된 과량의 NADH에 의한 간세포의 파괴, 간세포의 화학적 평형 저해, 대사 이상 및 미토콘드리아의 기능 저해에서 기인된다 (Bunsel R.G. 및 Lehmann A.G., Behav. Vrain Res. 1, 351(1980); 및 주 충노, 화학세계, 34, 767(1994)). These detrimental phenomena are due to the peroxidation reactions occurring in the production of acetaldehyde and the destruction of hepatocytes by excess NADH formed by the catalyst of MEOS, inhibition of hepatocyte chemical equilibrium, metabolic abnormalities and function of mitochondria (Bunsel RG and Lehmann AG, Behav.Vrain Res . 1, 351 (1980); and State Chungno, Chemical World, 34 , 767 (1994).
이러한 세포내 자유 라디칼의 생성은 세포질 내의 효소와 다양한 산화 효소로부터 형성된다. 이러한 자유 라디칼은 DNA와 미토콘드리아에 손상을 가져오며 원형질막에서는 지방 산화를 촉진시켜 지방간을 일으키게 된다 (Said E.M. 등, European Jounal of obsterics and gynecology and reproductive biology, 89, 1-6(2000)). 반면 생성된 자유 라디칼은 Cu-Zn 과산화물 디스뮤타아제(Cu-Zn SOD)에 의해서 H2O2로 전환되며, 이는 다시 글루타티온 환원효소 (glutathione reductase 5, GPX 5) 또는 항산화 효소인 카탈라아제에 의해서 H2O와 O2로 분리된다. 그러므로, Cu-Zn SOD와 GPX 5 등은 세포내의 산화를 회복하는 보조 역할을 한다고 할 수 있다 (Said E.M. 등). The production of these intracellular free radicals is formed from enzymes in the cytoplasm and various oxidases. These free radicals damage DNA and mitochondria and promote fatty oxidation in the plasma membrane, resulting in fatty liver (Said EM et al., European Jounal of obsterics and gynecology and reproductive biology, 89 , 1-6 (2000)). On the other hand, the generated free radicals are converted to H 2 O 2 by Cu-Zn peroxide dismutase (Cu-Zn SOD), which is in turn converted to glutathione reductase 5 (GPX 5) or antioxidant enzyme catalase. 2 O and O 2 are separated. Therefore, it can be said that Cu-Zn SOD, GPX 5 and the like play a secondary role in restoring cellular oxidation (Said EM, etc.).
알코올 대사 과정상에서는 아세트알데히드 외에 또 다른 독성 물질이 생산되 는데 이것이 바로 활성 산소라고 하는 고반응성의 산소 화합물들이다. 알코올 대사 과정에 있어서, 활성 산소는, 알코올 탈수소효소(alcohol dehydrogenase), ALDH 등의 탈수 효소들의 반응으로 인하여 체내의 산화 환원 상태가 붕괴되고 환원력이 고갈되어 나타나기도 하고, 마이크로롬(microsome)에 존재하는 마이크로좀 에탄올 산화효소계(microsomal ethanol oxidizing system), 크산틴 옥시다제(xanthine oxidase), 알데히드 옥시다제(aldehyde oxidase) 등의 직접적 산화 효소의 작용으로 발생되기도 한다.In alcohol metabolism, other toxic substances are produced besides acetaldehyde, which are highly reactive oxygen compounds called active oxygen. In the process of alcohol metabolism, active oxygen appears due to the reaction of dehydrating enzymes such as alcohol dehydrogenase, ALDH, etc. in the redox state of the body and depletion of reducing power, present in the microsome It is also generated by the action of direct oxidase such as microsomal ethanol oxidizing system, xanthine oxidase, aldehyde oxidase.
또한, 숙취 제거와 관련하여, 천연 식품 또는 한약 재료로부터 추출한 성분을 함유한 다양한 건강 보조 식품이 개발되고 있다(김정한 등, 한국농화학회지, 38(6): 549-553, 1995). 이러한 연구의 일환으로서, 이담 작용, 간장 해독, 간혈류 개선 작용, 지방의 흡수 촉진 작용 및 미세 담도를 통한 노폐물 배설 작용을 하는 콜린산류를 함유하는 조성물이 시판되고 있다. 이러한 콜린산의 예로서 간질환의 간 기능 개선, 간 기능 장애에 의한 전신 권태, 소화 불량, 식욕 부진, 육체 피로 등에 효과가 있다고 알려져 있는 우루소데옥시콜린산(ursodeoxycholic acid); 담석 용해제로 시판되고 있으며, 지방간 치료에 효과가 있어 경구 투여시 간 기능 개선 및 간 지방량 감소의 효과가 있는 타우로우루소데옥시콜린산(tauroursodeoxycholic acid); 담석 용해제로 시판되고 있는 체노데옥시콜린산(chenodeoxycholic acid); 및 디하이드로콜린산(dehydrocholic acid) 등이 있다. 그러나, 상기 콜린산류를 함유하는 조성물은 스트레스에 의한 부신 무게의 증가 및 비장의 위축 예방, 부신의 아스코르빈산 함량 변화 억제 및 혈액 생화학적 변화의 억제 등 스트레스로 인해 유발되는 일반적인 증상에 효과가 있음이 입증되었을 뿐, 숙취를 해소하거나 간장을 보호하는 효과에 대해서는 전혀 보고되어 있지 않다. In addition, in connection with the elimination of hangovers, various dietary supplements containing ingredients extracted from natural foods or herbal medicines have been developed (Kim Jung-han et al . , 38 (6): 549-553, 1995). As part of this research, a composition containing choline acids, which have an effect of edema, hepatic detoxification, hepatic blood flow improvement, promoting fat absorption, and excretion of waste products through fine bile ducts, is commercially available. Examples of such choline acid include ursodeoxycholic acid, which is known to be effective in improving liver function of liver disease, systemic malaise due to liver dysfunction, indigestion, anorexia, physical fatigue, and the like; Tauroursodeoxycholic acid, which is commercially available as a gallstone dissolving agent and is effective in treating fatty liver, which has an effect of improving liver function and reducing liver fat mass when orally administered; Chenodeoxycholic acid sold as a gallstone dissolving agent; And dehydrocholic acid. However, the composition containing choline acids is effective in the general symptoms caused by stress, such as increase in adrenal weight by stress and prevention of spleen atrophy, inhibition of ascorbic acid content of adrenal gland and suppression of blood biochemical changes This has been proven, and there is no report on the effects of relieving hangovers or protecting the liver.
또한, 한약재 또는 민간요법제로서 숙취해소에 유용한 효과가 있다고 알려져 있는 인삼, 가시오가피 등의 성분을 주성분으로 하는 각종 제제 형태의 의약품들이 개발되었다. 이 중에서, 인삼을 주성분으로 하는 자양 강장 드링크제가 다수 시판되고 있으며, 음주 후의 숙취제거를 위하여 각종 생약제를 포함하는 드링크제가 시판되고 있다. 이러한 드링크제는 음주 후에는 단독으로, 또한 음주 전에는 고알코올 함량의 주류에 첨가하여 음용되고 있다. 그러나, 일부 생약제를 함유하는 드링크제는 전신 권태, 복부 팽만감, 구토 또는 복통 등을 유발하는 경우가 있을 뿐 아니라, 일부 드링크제는 고가의 생약제를 사용함으로써 고가로 판매되는 등의 문제점이 있다. In addition, as a herbal medicine or a folk remedy, various types of medicines have been developed, which are mainly composed of ingredients such as ginseng and thorny ginseng, which are known to be useful in relieving hangovers. Among these, many nourishment tonic drink agents based on ginseng are commercially available, and drinks containing various herbal medicines are commercially available for removing hangover after drinking alcohol. These drinks are used alone after drinking, and in addition to alcohol with high alcohol content before drinking. However, a drink containing some herbal medicines may cause systemic boredom, abdominal bloating, vomiting or abdominal pain and the like, and some drink products are sold at high prices by using expensive herbal medicines.
그러나, 상기와 같이 음주 후 숙취 해소를 위한 다양한 노력에도 불구하고, 숙취를 효과적으로 완화하거나 해소할 수 있는 치료제나 음료의 개발은 그 요구에 비하여 아직까지 성공적이지 못한 편이다.However, despite various efforts to resolve hangovers after drinking as described above, the development of therapeutic agents or beverages that can effectively alleviate or eliminate hangovers has not been successful until now.
본 발명은 상기한 문제점을 해결하기 위해 인체에 부작용이 없으면서 음주로 인한 숙취 해소 전반에 대해서 우수한 효능을 갖는 새로운 숙취 해소용 조성물을 제공하는 것을 목적으로 한다. An object of the present invention is to provide a new hangover-relieving composition having an excellent effect on the overall hangover resolved by drinking without side effects in the human body to solve the above problems.
상기한 과제를 해결하기 위한 본 발명에 따른 숙취 해소용 조성물은, 활성 성분으로서 이온화칼슘 시비 현미를 알코올이나 열수로 추출하고, 상기 추출물에 설탕 또는 포도당, 말레인산, 젖산 또는 그 염, 페룰산, 타우린, 베타인을 용해시킨 것을 특징으로 한다.Hangover composition according to the present invention for solving the above problems is extracted with calcium or fertilized brown rice as an active ingredient with alcohol or hot water, sugar or glucose, maleic acid, lactic acid or its salts, ferulic acid, taurine to the extract It is characterized by dissolving betaine.
여기서, 본 발명은 활성 성분으로서 이온화칼슘 시비 현미를 1,000 내지 2,000 중량부, 상기 이온화칼슘 시비 현미에 추가하여 쇠뜨기 500 내지 800 중량부, 흑두 200 내지 400 중량부, 녹두 200 내지 400 중량부, 적소두 200 내지 400 중량부, 지구자 200 내지 400 중량부, 갈근 200 내지 400 중량부, 감초 100 내지 200 중량부, 진피 150 내지 250 중량부, 대추 30 내지 60 중량부, 갈화 400 내지 500 중량부, 미나리 400 내지 600, 무우 400 내지 600 중량부, 콩나물(대두 황권) 400 내지 600 중량부, 생강 30 내지 60 중량부, 칼슘 화합물 500 내지 800 중량부를 알코올이나 열수를 용매로서 이용하여 추출하고, 상기 추출물에 설탕 또는 포도당과, 말레인산, 젖산 또는 그 염, 페룰산, 타우린, 베타인을 용해시킨 숙취 해소용 조성물을 제공한다. Here, the present invention is 1,000 to 2,000 parts by weight of calcium ion fertilized brown rice as the active ingredient, 500 to 800 parts by weight, 200 to 400 parts by weight of black bean, 200 to 400 parts by weight, red bean 200 in addition to the calcium ionized brown rice To 400 parts by weight, earth 400 to 400 parts by weight, brown root 200 to 400 parts by weight, licorice 100 to 200 parts by weight, dermis 150 to 250 parts by weight, jujube 30 to 60 parts by weight, 400 to 500 parts by weight, buttercup 400 To 600, 400 to 600 parts by weight of radish, 400 to 600 parts by weight of bean sprouts (soybean rhubarb), 30 to 60 parts by weight of ginger, 500 to 800 parts by weight of calcium compound are extracted using alcohol or hot water as a solvent, and the sugar is extracted into the extract. Or it provides a hangover composition for dissolving glucose, maleic acid, lactic acid or salts thereof, ferulic acid, taurine, betaine.
이때 상기 이온화칼슘 시비 현미는 이온화 칼슘으로서 패각 이온화 칼슘, 예를 들면 뉴카리온 제제(대한민국 특허 공개번호 2006-0034085)를 비료형식으로 투여한 현미가 바람직하다. 이온화 칼슘 시비 현미는 칼슘이 144ppm 가량 포함되어 있으나 일반 현미는 44ppm 정도로 칼슘의 함유량이 크게 차이가 난다.At this time, the calcium ion fertilized brown rice is an ionized calcium shell shell ion, for example, a brown rice in the form of a fertilizer, such as nucarion preparation (Korean Patent Publication No. 2006-0034085). Ionized calcium fertilized brown rice contains about 144ppm of calcium, but ordinary brown rice has a large difference in calcium content of about 44ppm.
칼슘 화합물로는 인체에의 흡수도가 높은 화합물이 바람직하며, 패각 칼슘, 모려 칼슘, 해조 칼슘, 유청 칼슘, 진주 칼슘(전복, 가리비 등의 패각과 진주 칼슘 포함), 기타 칼슘염, 예를 들면 칼슘 아세테이트(calcium acetate), 칼슘 아스코르베이트(calcium ascorbate), 칼슘 글루코네이트(calcium gluconate), 칼슘 아이오데이트(calcium iodate), 칼슘 아이오다이드(calcium iodide), 칼슘 나이트레이트(calcium nitrate), 칼슘 옥살레이트(calcium oxalate), 칼슘 옥사이드(calcium oxide), 인산칼슘(calcium phosphate), 칼슘 파이로포스페이트(calcium pyrophosphate), 칼슘 실리케이트(calcium silicate), 칼슘 설페이트(calcium sulfate), 칼슘 설파이트(calcium sulfite) 등이 단독으로 또는 혼합되어 사용될 수 있다.As the calcium compound, a compound having high absorption into the human body is preferable, and shell calcium, cured calcium, seaweed calcium, whey calcium, pearl calcium (including shells such as abalone and scallops and pearl calcium), other calcium salts, for example Calcium acetate, Calcium ascorbate, Calcium gluconate, Calcium iodate, Calcium iodide, Calcium iodide, Calcium nitrate, Calcium Oxalate, calcium oxide, calcium phosphate, calcium pyrophosphate, calcium silicate, calcium sulfate, calcium sulfite ) May be used alone or in combination.
상기 숙취 해소용 조성물은 상기 추출물 부피의 3배 내지 6배로 희석하여 사용할 수 있으며, 상기 추출물을 희석하는 희석제로는 증류수가 바람직하다. The hangover composition may be diluted to 3 to 6 times the volume of the extract, distilled water is preferred as a diluent to dilute the extract.
또한, 본 발명에 따른 숙취 해소용 조성물은, 상기와 같은 활성 성분 이외에도, 조성물의 생체 활성 효과를 보강하기 위한 보조 성분으로서, 비타민 B1, B2, B6, B12, C, 판토텐산, 니코틴산 아미드, 엽산, 비오틴, 아연, 철, 칼슘, 마그네슘 또는 각종 비타민과 미네랄의 공급 목적으로 하는 효모 추출물 등의 혼합물을 더 함유할 수 있다. In addition, the hangover relief composition according to the present invention, in addition to the active ingredient as described above, as an auxiliary component for reinforcing the bioactive effect of the composition, vitamin B 1 , B 2 , B 6 , B 12 , C, pantothenic acid, nicotinic acid It may further contain a mixture of amide, folic acid, biotin, zinc, iron, calcium, magnesium or yeast extract for the purpose of supplying various vitamins and minerals.
이 때, 본 발명의 조성물은 상기 비타민 등의 보조 성분을 조성물 전체 중량에 대하여 0.01 내지 10 중량%의 양으로 함유하는 것이 바람직하며, 특히 비타민 B1, B2 및 C를 함유하는 경우, 조성물 전체 중량에 대하여 각각 0.01 내지 3 중량%, 0.01 내지 3 중량% 및 0.01 내지 4 중량%의 양으로 함유하는 것이 가장 바람직하다. At this time, the composition of the present invention preferably contains an auxiliary component such as vitamins in an amount of 0.01 to 10% by weight based on the total weight of the composition, especially in the case of containing vitamins B 1 , B 2 and C, Most preferably, the amount is contained in an amount of 0.01 to 3% by weight, 0.01 to 3% by weight and 0.01 to 4% by weight, respectively.
또한, 본 발명의 숙취 해소용 조성물은 약학적 또는 생리학적으로 허용 가능한 담체를 추가로 함유할 수 있다. 상기 담체로서, 본 발명이 속하는 기술 분야에 알려진 기능성 조성물의 제조 방법에 따라 약학적 또는 생리학적으로 허용되는 모든 담체를 함유할 수 있으며, 예컨대, 락토오즈, 덱스트로즈, 수크로즈, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로즈, 폴리비닐피롤리돈, 물, 메틸 하이드록시벤조에이트, 프로필 하이드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유 등을 함유할 수 있다. 또한, 본 발명의 숙취 해소용 조성물은 충진제, 항응집제, 윤활제, 습윤제, 향료, 유화제 또는 방부제 등을 추가로 함유할 수 있다. In addition, the hangover composition of the present invention may further contain a pharmaceutically or physiologically acceptable carrier. As the carrier, it may contain all carriers pharmaceutically or physiologically acceptable according to the preparation method of the functional composition known in the art, for example, lactose, dextrose, sucrose, sorbitol, mannitol Xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate , Talc, magnesium stearate, mineral oil and the like. In addition, the hangover composition of the present invention may further contain a filler, anti-coagulant, lubricant, wetting agent, fragrance, emulsifier or preservative.
또한, 본 발명의 조성물은 매실향, 레몬향, 파인애플향 또는 허브향 등의 천연 향료, 천연 과즙, 클로르필린(chlorphyllin) 등의 천연 색소, 과당, 벌꿀, 당알 코올, 설탕 등의 감미제 및/또는 구연산, 구연산 나트륨 등의 산미제 또는 이들의 혼합물을 추가로 함유할 수 있다. In addition, the composition of the present invention, natural flavors such as plum flavor, lemon flavor, pineapple flavor or herbal flavor, natural fruit juice, natural pigments such as chlorphyllin, sweeteners such as fructose, honey, sugar alcohol, sugar and / or It may further contain an acidulant such as citric acid, sodium citrate or a mixture thereof.
본 발명에 따른 천연 약재 자체 또는 이들의 추출물을 함유하는 숙취 해소용 조성물은 투여 후, 활성 성분의 방출 속도를 조절하기 위하여 (예컨대, 신속, 지속 또는 지연 방출), 이 발명이 속하는 기술 분야에 잘 알려진 방법으로 제형화될 수 있다. 상기 제형은 정제, 알약, 분말, 새세이(sachet), 엘릭서(elixir), 현탁액, 에멀젼, 용액, 시럽, 에어로졸, 연질 또는 경질 젤라틴 캡슐, 멸균 주사 용액, 멸균 분말 등의 형태일 수 있다. Hangover-relieving compositions containing the natural medicinal herb or extracts thereof according to the present invention are well known in the art to control the release rate of the active ingredient (eg, rapid, sustained or delayed release) after administration. It can be formulated in a known manner. The formulations may be in the form of tablets, pills, powders, sachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols, soft or hard gelatin capsules, sterile injectable solutions, sterile powders and the like.
또한, 본 발명에 따른 숙취 해소제는 경구, 경피, 피하, 정맥 또는 근육 등의 여러 경로를 통하여 투여될 수 있으나, 경구 투여 방법을 이용하는 것이 가장 바람직하다. In addition, hangover relieving agent according to the present invention can be administered through various routes such as oral, transdermal, subcutaneous, intravenous or intramuscular, it is most preferred to use an oral administration method.
본 발명에 따른 숙취 해소용 조성물의 1회 인체 투여량은, 천연 약재 자체를 함유하는 조성물의 경우에는 15g 내지 25g인 것이 바람직하고, 상기 천연 약재의 추출물을 함유하는 조성물의 경우에는 3g 내지 10g이 바람직하고, 4 내지 6 g 범위인 것이 보다 바람직하지만, 실제 투여량은 투여 경로, 환자의 연령, 성별, 체중 및 증상의 경중 등과 같은 여러 가지 인자를 고려하여 결정되어야 하며, 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다. The single human dose of the composition for relieving hangover according to the present invention is preferably 15 g to 25 g in the case of the composition containing the natural medicine itself, and 3 g to 10 g in the case of the composition containing the extract of the natural medicine. Preferably, it is more preferably in the range of 4 to 6 g, but the actual dosage should be determined in consideration of various factors such as the route of administration, the age, sex, weight of the patient, and the severity of the symptoms. It does not limit the scope of the present invention.
또한, 본 발명은 상기 숙취 해소용 조성물을 제조하는 방법을 제공하며, 본 발명에 따른 숙취 해소용 조성물 제조방법은 이온화칼슘 시비 현미 1,000 내지 2,000 중량부, 쇠뜨기 500 내지 800 중량부, 흑두 200 내지 400 중량부, 녹두 200 내지 400 중량부, 적소두 200 내지 400 중량부, 지구자 200 내지 400 중량부, 갈근 200 내지 400 중량부, 감초 100 내지 200 중량부, 진피 150 내지 250 중량부, 대추 30 내지 60 중량부, 칼슘 화합물 500 내지 800 중량부에 70 내지 95%의 에탄올을 상기 혼합물 중량의 4 내지 8배의 양으로 첨가한 후, 40 ℃ 내지 90 ℃, 바람직하게는 60℃ 내지 85℃에서, 2시간 내지 6시간, 바람직하게는 4시간 동안 추출하고 감압 건조하여 농축 천연 추출물을 얻는 단계와, 갈화 400 내지 500 중량부, 미나리 400 내지 600, 무우 400 내지 600 중량부, 콩나물(대두 황권) 400 내지 600 중량부, 생강 30 내지 60 중량부에 70 내지 95%의 에탄올을 상기 혼합물 중량의 4 내지 8배의 양으로 첨가한 후, 40 ℃ 내지 90 ℃, 바람직하게는 60℃ 내지 85℃에서, 10분 내지 30분, 바람직하게는 20분 동안 추출하고 감압 건조하여 농축 천연 추출물을 얻는 단계, 및 상기 두 단계의 추출물을 혼합하고 설탕 또는 포도당과, 말레인산, 젖산 또는 그 염, 추가로 페룰산, 타우린, 베타인을 상기 추출물에 용해시키는 단계를 포함하여 이루어진다. 상기 방법에 의하는 경우, 총 중량이 25kg의 천연 약재 혼합물을 추출 및 감압 건조시키면, 대략 5.0kg의 농축 추출물을 얻을 수 있다.In addition, the present invention provides a method for preparing the hangover relief composition, the method for preparing a hangover relief according to the present invention 1,000 to 2,000 parts by weight of calcium ion fertilized brown rice, 500 to 800 parts by weight of horsetail, 200 to 400 black bean Parts by weight, green beans 200 to 400 parts by weight, red beans 200 to 400 parts by weight, earth flakes 200 to 400 parts by weight, brown root 200 to 400 parts by weight, licorice 100 to 200 parts by weight, dermis 150 to 250 parts by weight, jujube 30 to 60 By weight, 500 to 800 parts by weight of the calcium compound, 70 to 95% of ethanol is added in an amount of 4 to 8 times the weight of the mixture, and then at 40 ° C. to 90 ° C., preferably 60 ° C. to 85 ° C., 2 Extracting for hours to 6 hours, preferably 4 hours, and drying under reduced pressure to obtain a concentrated natural extract, 400 to 500 parts by weight, 400 to 600 buttercups, 400 to 600 parts by weight of radish, 400 to 600 parts by weight of bean sprouts (soybean yellow bean) 400 to600 parts by weight, 30 to 60 parts by weight of ginger, 70 to 95% of ethanol is added in an amount of 4 to 8 times the weight of the mixture, and then 10 to 40 ° C. to 90 ° C., preferably 60 ° C. to 85 ° C. Extraction for 30 minutes to 30 minutes, preferably 20 minutes, and dried under reduced pressure to obtain a concentrated natural extract, and the extracts of the two steps are mixed and sugar or glucose, maleic acid, lactic acid or its salts, further ferulic acid, taurine , Solubilizing betaine in the extract. According to the above method, when the total weight of the extract of 25 kg of natural medicinal herb mixture is extracted and dried under reduced pressure, approximately 5.0 kg of concentrated extract can be obtained.
또한, 본 발명의 숙취 해소용 조성물의 제조 방법은, 이온화칼슘 시비 현미 1,000 내지 2,000 중량부, 쇠뜨기 500 내지 800 중량부, 흑두 200 내지 400 중량부, 녹두 200 내지 400 중량부, 적소두 200 내지 400 중량부, 지구자 200 내지 400 중량부, 갈근 200 내지 400 중량부, 감초 100 내지 200 중량부, 진피 150 내지 250 중량부, 대추 30 내지 60 중량부,칼슘 화합물 500 내지 800 중량부에 물을 상기 혼합물 중량의 4 내지 8배의 양으로 첨가한 후, 90 ℃ 내지 120 ℃, 바람직하게는 110℃에서, 2시간 내지 6시간, 바람직하게는 4시간 동안 추출하고 감압 건조하여 농축 천연 추출물을 얻는 단계와, 갈화 400 내지 500 중량부, 미나리 400 내지 600, 무우 400 내지 600 중량부, 콩나물(대두 황권) 400 내지 600 중량부, 생강 30 내지 60 중량부에 물을 상기 혼합물 중량의 4 내지 8배의 양으로 첨가한 후, 90 ℃ 내지 120 ℃, 바람직하게는 110℃에서, 10분 내지 30분, 바람직하게는 20분 동안 추출하고 감압 건조하여 농축 천연 추출물을 얻는 단계를 포함한다. In addition, the method for producing a hangover elimination composition of the present invention, 1,000 to 2,000 parts by weight of calcium ion fertilized brown rice, 500 to 800 parts by weight of horsetail, 200 to 400 parts by weight of black bean, 200 to 400 parts by weight of mung bean, 200 to 400 parts by red bean To 200 parts by weight, earth 400 to 400 parts by weight, 200 to 400 parts by weight, licorice 100 to 200 parts by weight, dermis 150 to 250 parts by weight,
상기 방법에 의하여 두 단계 추출물을 합할 경우, 25kg의 천연 약재 혼합물을 추출하여 가열 및 농축하여 약 5.4kg의 농축 추출물을 얻는 것이 바람직하다. 이때, 본 발명의 제조 방법에 있어서 추출에 사용되는 알코올 또는 물의 양, 추출 온도 및 추출 시간을 상기 범위로 하여야 적정한 농도의 추출물을 얻을 수 있다.When the two step extracts are combined by the above method, it is preferable to extract 25 kg of the natural medicinal herb mixture, heat and concentrate to obtain a concentrated extract of about 5.4 kg. At this time, the amount of alcohol or water used for extraction in the production method of the present invention, the extraction temperature and extraction time should be in the above range to obtain an extract of the appropriate concentration.
본 발명은 칼슘 화합물을 주성분으로 하는 천연물 성분들과 비타민 등 첨가제가 혼합된 조성물이 인체에 대한 부작용 없이 뛰어난 숙취 해소 효과를 나타내는 것에 그 특징이 있다.The present invention is characterized in that the composition of the additives, such as vitamins and natural ingredients containing calcium compounds as a main component exhibits an excellent hangover relief effect without side effects on the human body.
본 발명은 알코올 대사 및 배설에 관한 기작에 의거, 알코올 음용시 대사 과정에서 NAD와 NADH의 비율을 조절시킴으로써, 알코올의 배설을 빠르게 하고 아세트알데히드의 농도를 최대한 억제시킴과 동시에, 알코올 분해 과정에서 다량 생성되는 활성 산소도 억제하여, 궁극적으로 알코올 흡수에 의하여 취하는 현상과 그 다음에 오는 숙취 현상을 근본적으로 제거하는 건강 기능성 조성물과 그 제조 방법을 제공한다.According to the mechanism of alcohol metabolism and excretion, by controlling the ratio of NAD and NADH in the metabolic process when drinking alcohol, to speed up the excretion of alcohol and to suppress the concentration of acetaldehyde as much as possible, in the alcohol decomposition process The present invention also provides a health functional composition and a method for producing the same, which inhibit the generated free radicals and ultimately eliminate the phenomenon caused by alcohol absorption and the following hangover phenomenon.
알코올이 인체에 흡입되면 다음과 같은 대사 경로를 통해 산화되는바, 간과 위장관에 존재하는 ADH(Alcohol Dehydrogenase)와 ALDH(Aldehyde Dehydrogenase)의 작용으로 대사된다. When alcohol is inhaled into the body, it is oxidized through the following metabolic pathways, which are metabolized by the action of alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) present in the liver and gastrointestinal tract.
본 발명자 등은 알코올의 흡수, 분포, 대사, 배설(ADME: Absorption, Distribution, Metabolism, Excretion)의 메카니즘을 심층 연구한 결과, 알코올에 의한 숙취는 음주 시작 30분 이내에 흡수되는 알코올에 의한 것이 매우 중요함을 발견하였다. The present inventors have studied in depth the mechanism of absorption, distribution, metabolism and excretion of alcohol (ADME), and as a result, it is very important that the hangover caused by alcohol is absorbed by alcohol absorbed within 30 minutes of the start of drinking. Was found.
음주 초기에는 인체가 알코올을 숙취의 주범인 아세트알데히드를 생성하는 일차 대사 과정이 일어나며, 대사 효소 ADH 및 보조 효소 NAD(Nicotinamide Adenine dinucleotide)에 의해 간이나, 위에서 일차로 대사되어 아세트알데히드가 생성된다. 두 번째의 대사 과정은 ALDH 효소에 의한 아세트알데히드가 초산(acetic acid)으로 산화되는 과정이다. 그런데, 인체가 충분한 양의 ALDH를 항상 보유 하고 있지 않기 때문에 숙취 원인 물질인 아세트알데히드를 산화시키는 2차 대사 반응이 일차 대사에 비하여 느린 반응 속도를 가질 수 있다. 그러므로 인체가 충분한 양의 ALDH 효소를 생산(transcription)해내는 시점까지는 알코올의 흡수에 따라 다량의 아세트알데히드가 축적되는 것이 필연적으로 수반된다.In the early stages of drinking, the human body produces alcohol, the primary metabolic process that produces acetaldehyde, the main culprit of hangover, and is metabolized primarily by the metabolic enzyme ADH and coenzyme NAD (Nicotinamide Adenine dinucleotide) to produce acetaldehyde. The second metabolic process is the oxidation of acetaldehyde with acetic acid by the ALDH enzyme. However, since the human body does not always have a sufficient amount of ALDH, the secondary metabolic reaction of oxidizing acetaldehyde, which is a hangover-causing substance, may have a slower reaction rate than the primary metabolism. Therefore, until the body produces a sufficient amount of ALDH enzyme (transcription) it is inevitably accompanied by the accumulation of a large amount of acetaldehyde in accordance with the absorption of alcohol.
이에 본 발명자는 초기 알코올의 일차 대사 반응 속도를 억제하는 방법을 발명하게 되었다. 즉 알코올의 일차 대사 반응을 억제하기 위하여 흡수도가 높은 칼 슘 화합물을 조성물에 활성 성분으로 사용하여 인체의 신호 전달 체계를 활성화 시킴으로써 신속하게 ALDH가 생성되게 함과 동시에, 설탕 혹은 포도당을 투여하거나 이온화칼슘 시비 현미를 투여하는 방법으로 칼슘과 쌀 녹말 분해 포도당을 동시에 투여함으로써 알코올보다 이것들이 우선적으로 대사되도록 하는 방법을 이용하여, 일차 대사 반응의 필수 보조 효소인 NAD가 알코올의 일차 대사 과정에 음주 초기 일정 시간 참여하지 못하게 하는 것이다. The present inventors have therefore invented a method of inhibiting the rate of primary metabolic reaction of early alcohol. In other words, calcium compounds with high absorption are used as active ingredients in the composition to suppress the first metabolic reaction of alcohol, thereby activating the signal transduction system of the human body to rapidly produce ALDH, and to administer or ionize sugar or glucose. Calcium fertilized brown rice is administered to both the calcium and rice starch-degrading glucose at the same time, so that they are metabolized preferentially over alcohol. It is to prevent you from participating in a certain time.
즉, 음주 초기에 충분한 양의 ALDH(알코올 분해 두 번째 단계 주효소)가 생성되기 전까지 일차 대사 과정의 속도를 억제함으로써, 과다한 아세트알데히드가 생성되지 않게 하려는 목적으로 설탕, 포도당 등의 흡수가 매우 신속한 탄수화물과 녹말성분의 이온화칼슘 시비 현미를 조성물에 첨가하였다. 이들 탄수화물은 인체에서 잘 알려져 있는 해당 글루코스 대사 경로(Glycolytic Pathway, 도 1)를 따라 신속하게 대사되어 글루코스 6-포스페이트(Glucose 6-phosphate), 프럭토스 6-포스페이트(Fructose 6-phosphate), 프럭토스 1,6-비스포스페이트(Fructose1,6-phosphate) 등을 거쳐 글리세랄데하이드 3-포스페이트(Glyceraldehyde 3-phosphate)를 생성한다. In other words, by suppressing the rate of primary metabolic processes until a sufficient amount of ALDH (Alcohol Decomposition Second Enzyme) is produced at the beginning of drinking, the absorption of sugar, glucose, etc. is very rapid for the purpose of preventing excess acetaldehyde from being produced. Carbohydrate and starch-ionized calcium fertilized brown rice were added to the composition. These carbohydrates are rapidly metabolized along the corresponding Glycolytic Pathway (FIG. 1), which is well known in the body, such as glucose 6-phosphate, fructose 6-phosphate, and fructose. Glyceraldehyde 3-phosphate is produced through 1,6-bisphosphate (Fructose1,6-phosphate).
생성된 글리세랄데하이드-3-포스페이트는 곧바로 1, 3-비스포스포글리세레이트(1,3-biphosphoglycerate)로 전환되는 바, 이때 NAD가 주 효소로서 작용한다(Lubert Stryer, Biochemistry 4th Ed. 490쪽). The resulting glyceraldehyde-3-phosphate is converted directly to 1,3-biphosphoglycerate, where NAD acts as the main enzyme (Lubert Stryer, Biochemistry 4th Ed. P. 490). ).
그러므로 투여한 설탕 혹은 포도당의 대사에 NAD가 우선적으로 사용되고 알코올 대사에는 사용되지 못하게 됨으로써, 알코올의 1차 대사 반응이 저해되어 음 주 초기 과다한 양의 아세트알데히드의 생성이 억제된다. 흡수된 알코올은 신장에서 소변 등으로 대사 되지 않은 채 그대로 배설되는 확률이 높아지는 결과를 가져온다. 대사 되지 않고 체외로 배출되는 에틸알코올 양이 많을수록 아세트알데히드의 생성이 적어지고, 당연히 숙취도 줄어드는 효과를 가진다.Therefore, NAD is preferentially used for the metabolism of sugar or glucose, which is not used for alcohol metabolism, thereby inhibiting the primary metabolic reaction of alcohol and suppressing the production of excessive amount of acetaldehyde at the beginning of drinking. Absorbed alcohol results in a higher probability of excretion of the kidneys without being metabolized in the kidneys. The greater the amount of ethyl alcohol that is released into the body without metabolism, the less acetaldehyde is produced, and of course, the hangover is also reduced.
설탕과 포도당 외에도 상기 글루코스 대사 경로에서의 중간체인 글루코스 6-포스페이트(Glucose 6-phosphate), 프럭토스 6-포스페이트(Fructose 6-phosphate), 프럭토스 1,6-비스포스페이트(Fructose1,6-phosphate) 등도 설탕등과 마찬가지로 NAD를 알코올 대사보다 우선적으로 사용하는 효능이 있어 이를 대신 첨가 할 수 도있다.In addition to sugar and glucose, glucose 6-phosphate, fructose 6-phosphate, fructose 1,6-bisphosphate, which are intermediates in the glucose metabolic pathway Like sugar, etc., NAD has the effect of using NAD over alcohol metabolism, so it can be added instead.
이외에도 본 발명자들은 글루코스 대사 경로 외의 생체 내 반응에서 NAD 가 우선적으로 사용되는 반응을 연구 한 결과 말레인산 및 그염(Maleic acid 및 maleate salt)과 젖산 및 그 염(Lactic acid 및 lactate salt)가 NAD를 사용함을 알아내었다. 그러므로 이런 산 및 염도 설탕과 포도당, 이온화칼슘 시비(비료 형식으로 투여한) 현미 외에 알코올보다 우선적으로 NAD를 사용하는 효능으로 알코올의 대사를 지연시켜 몸밖으로 배출 시키며 충분한 양의 ALDH가 생성될 때 까지 알코올 의 1차 대사를 억제하는 효능으로 숙취를 예방한다(Citric acid cycle, Lubert Stryer, Biochemistry 4th Ed. 513쪽, Glyoxalate cycle, Lubert Stryer, Biochemistry 4th Ed. 523쪽, Glycolysis, Lubert Stryer, Biochemistry 4th Ed. 497쪽)).In addition, the present inventors studied the reaction in which NAD is preferentially used in in vivo reactions other than the glucose metabolic pathway, indicating that maleic acid and its salts (Maleic acid and maleate salts) and lactic acid and its salts (Lactic acid and lactate salts) use NAD. Figured out. Therefore, in addition to sugar, glucose, and ionized calcium fertilized (fertilized) brown rice, these acids and salts have the effect of using NAD over alcohol, which delays the metabolism of alcohol and releases it out of the body until a sufficient amount of ALDH is produced. Prevents hangovers by inhibiting primary metabolism of alcohol (Citric acid cycle, Lubert Stryer, Biochemistry 4th Ed.p. 513, Glyoxalate cycle, Lubert Stryer, Biochemistry 4th Ed.p. 523, Glycolysis, Lubert Stryer, Biochemistry 4th Ed) P. 497).
주성분인 이온화칼슘 시비 현미에 포함된 이온화칼슘 화합물과 부성분으로 첨가되는 칼슘 화합물은 인체의 신호 전달 체계를 활성화하여, 음주 초기 ALDH의 생성을 촉진하여 일차 대사에서 생성된 아세트알데히드의 2차 대사 반응을 신속하게 진행되도록 하는 역할을 한다.The ionized calcium compound contained in the fermented brown rice, the main component, and the calcium compound added as a minor component activate the signal transduction system of the human body, promote the production of ALDH in the early stage of drinking, and stimulate the secondary metabolic reaction of acetaldehyde produced in primary metabolism. It plays a role in speeding up the process.
그 중에서도 이온화칼슘 시비(비료 형식으로 투여한) 현미의 이온화 칼슘 성분은 인체의 흡수도가 매우 높아 인체 신호 전달 체계 활성화의 주된 역할을 수행한다. Among them, the ionized calcium component of brown rice fertilized (administered in the form of fertilizer) has a very high absorption of the human body and plays a major role in activating the human body signaling system.
칼슘은 인체에 가장 많이 존재하는 무기 원소로서 인체의 약 2%인 1,200g 을 인체가 보유하고 있고 각종 효소의 활성화 및 세포 내, 세포 간의 신호 전달 체계에서 매우 중요한 역할을 수행하고 있다. Calcium is the most abundant inorganic element in the human body, and the human body holds about 1,200 g, which is about 2% of the human body, and plays a very important role in the activation of various enzymes and signal transduction systems within and between cells.
즉, 칼슘 화합물의 첨가는 위장 내의 pH를 알칼리로 변환시킴으로써 알코올의 흡수를 억제함과 동시에 인체에서의 이온 균형(ion balance) 및 NAD, NADH, ADH, ALDH 등 각종 효소 활성화 및 글루코스 대사(glycolysis)의 변환을 가져온다.(Maria V. Zamaraeva et al. Ca2+-dependent glycolysis activation mediates apoptotic ATP elevation in HeLa cells, Biochemical and Biophysical Research Communications Vol. 363, (3), 2007, pp 687-693)In other words, the addition of calcium compounds inhibits the absorption of alcohol by converting the pH in the stomach into alkali, and simultaneously activates various enzymes such as ion balance, NAD, NADH, ADH, and ALDH, and glucose metabolism in the human body. (Maria V. Zamaraeva) et al. Ca 2+ -dependent glycolysis activation mediates apoptotic ATP elevation in HeLa cells, Biochemical and Biophysical Research Communications Vol. 363, (3), 2007, pp 687-693)
또한 체내 세포 내, 세포 간의 신호 전달 체계를 활성화 하여 알코올 대사에 관련된 각종 효소 및 보조 효소, 보조 요인(Co-factor) 등의 원활한 생산 및 공급을 활성화 함으로써, 아세트알데히드및 유해 산소의 축적을 방지하는 메카니즘으로 숙취를 예방한다. In addition, by activating the signal transduction system within the body and between cells, it facilitates the smooth production and supply of various enzymes, coenzymes, and co-factors related to alcohol metabolism, thereby preventing the accumulation of acetaldehyde and harmful oxygen. Mechanisms prevent hangovers.
특히 칼슘의 부족은 세포의 산성화 및 유해 산소 발생을 초래하여 뇌세포 파괴에 의한 두통 등 또 다른 숙취의 원인을 제공하므로 본 칼슘 화합물 주성분의 조성물은 숙취에 있어서, 알코올 음용으로 생성되는 주요 독성 물질 아세트알데히드 생성을 억제할 뿐 아니라, 알코올 대사 과정에서 활성 산소가 다량으로 발생하여 이들이 알코올성 장애를 초래하는 것도 방지하는 효능을 가진다. In particular, the lack of calcium leads to acidification of cells and generation of harmful oxygen, which provides another cause of hangover, such as headache caused by brain cell destruction, so the composition of the main ingredient of this calcium compound is a major toxic substance acetase produced by alcohol consumption during hangover. In addition to inhibiting aldehyde production, active oxygen is generated in a large amount in the process of alcohol metabolism, which has the effect of preventing them from causing alcoholic disorders.
본 발명에서 이온화칼슘 시비 현미의 이온화칼슘 화합물로는 인체에의 흡수도가 높은 화합물이 바람직하며, 높은 이온화 정도를 가지게 됨으로써 피 투여자에 대하여 칼슘 흡수율이 월등히 높고 필수 원소 등의 유익한 원소도 제공하는 패각 이온화칼슘(뉴카리온 제제, 대한민국 특허 공개번호 2006-0034085)이 바람직하며, 본 발명에서 부성분으로 첨가되는 칼슘 화합물은 패각 칼슘, 진주칼슘, 굴껍질에서 추출한 모려 칼슘, 다공성 구조로 소화 흡수율이 높은 바다의 홍조류에서 제조되는 해조 칼슘, 칼슘 흡수를 증진 시키는 성분이 함유된 우유에서 추출한 유청 칼슘, 기타 칼슘염, 예를 들면 칼슘 아세테이트(calcium acetate), 칼슘 아스코르베이트(calcium ascorbate), 칼슘 글루코네이트(calcium gluconate), 칼슘 아이오데이트(calcium iodate), 칼슘 아이오다이드(calcium iodide), 칼슘 타이트레이 트(calcium nitrate), 칼슘 옥살레이트(calcium oxalate), 칼슘 옥사이드(calcium oxide), 칼슘(calcium phosphate), 칼슘 파이로포스페이트(calcium pyrophosphate), 칼슘 실리케이트(calcium silicate), 칼슘 설페이트(calcium sulfate), 칼슘 설파이드(calcium sulfite) 등이 단독으로 또는 혼합하여 사용될 수 있다.In the present invention, as the ionized calcium compound of calcium ion fertilized brown rice, a compound having high absorption into the human body is preferable, and by having a high degree of ionization, the calcium absorption rate is extremely high and beneficial elements such as essential elements are provided to the recipient. Shell ionized calcium (Nucharion preparation, Korean Patent Publication No. 2006-0034085) is preferred, and the calcium compound added as a minor component in the present invention is the shell calcium, pearl calcium, hydrated calcium extracted from oyster shell, digestion absorption rate Seaweed calcium from high sea red algae, whey calcium extracted from milk containing ingredients that enhance calcium absorption, other calcium salts, such as calcium acetate, calcium ascorbate, calcium gluco Calcium Gluconate, Calcium Iodate, Calcium Iodide dide), calcium nitrate, calcium oxalate, calcium oxide, calcium phosphate, calcium pyrophosphate, calcium silicate, calcium silicate Sulfate (calcium sulfate), calcium sulfite (calcium sulfite) and the like can be used alone or in combination.
칼슘 주성분 외에 보조 성분으로 쇠뜨기, 흑두, 녹두, 적소두, 지구자, 갈근, 감초, 진피, 대추 등의 물 혹은 알코올 추출물과 갈화, 미나리, 무우, 콩나물(대두황권), 생강 등의 물 혹은 알코올 추출물을 첨가한 후 최종적으로 추출물의 중량대비 10 내지 30%의 설탕 혹은 포도당과, 말레인산, 젖산또는 각각의 염 2 내지 중량5%를 용해시켜 제조하여 본 발명의 조성물이 완성된다. In addition to the main calcium components, water or alcohol extracts such as horsetail, black bean, mung bean, red bean bean, earth flakes, brown root, licorice, dermis, jujube, and water or alcohol extracts such as browning, buttercup, radish, bean sprouts (soybean rhubarb) and ginger After the addition of 10 to 30% of the sugar or glucose, and maleic acid, lactic acid or 2 to 5% by weight of each salt is finally prepared by dissolving the weight of the extract to complete the composition of the present invention.
본 발명에서 사용되는 구성 요소를 각각 설명하면 다음과 같다.The components used in the present invention will be described as follows.
이온화칼슘을 비료 형식으로 투여한 이온화칼슘 시비 현미는 두 가지 효능을 동시에 나타내는 요소로서 자체가 녹말로서 추출 과정에서 녹말이 포도당으로 분해되어 알코올 대사 1차 반응에 참여하는 NAD를 사용하게 하는 기전으로 알코올의 대사억제를 수행하여 배설을 촉진함과 동시에,칼슘 성분은 인체 신호 전달 체계 활성화로 알코올의 2차 대사, 즉 아세트알데히드의 분해에 주 효소인 ALDH의 생산을 활성화 하여 숙취 원인인 아세트알데히드의 생성을 억제하는 복합 기능을 가진다.Calcium-ion fertilized brown rice, which has been administered in the form of fertilizer, is a starch that shows both effects simultaneously. In addition to promoting excretion by inhibiting metabolism, calcium component activates the human body's signal transduction system, thereby activating secondary metabolism of alcohol, ie, the production of ALDH, a major enzyme in the decomposition of acetaldehyde, to produce acetaldehyde, a hangover cause. Has a complex function to suppress.
쇠뜨기(Equisetum arvense)는 양치 식물로서 이루어진 속새과(Equisetaceae)에 속하는 다년생 초본 식물로서 전 세계적으로 30여종이 북반구의 온대지방을 중심으로 널리 분포한다. 우리나라에 흔히 밭둑 등에서 발견되며 땅위 줄기의 두 종 류 중 하나는 포자를 만드는 생식 줄기이고,다른 하나는 포자를 생성하지 않는 영양 줄기이다. 영양 줄기를 가을에 캐서 말린 것을 문형이라고 하고 이뇨제나 지혈제로 쓰인다. 속새과 식물들은 약리 성분을 많이 포함하고 있어 항저혈당, 이뇨 작용, 간 보호 기능이 있다. 유럽 아시아, 아메리카에서는 피부 항염제로 사용되고,터키나 미국에서는 항균제로도 사용한다. 이외에도 쇠뜨기 추출물이 제 2형 인슐린 비의존성 당뇨에서 혈당 조절 활성을 나타낸다는 보고가 있다.Equisetum arvense is a perennial herbaceous plant belonging to the Equisetaceae, which is a fern, and is distributed around 30 temperate regions in the northern hemisphere. It is commonly found in field banks in Korea. One of the two types of stems on the ground is the reproductive stems that make spores, and the other is the nutrient stem that does not produce spores. Nutritious stems are dried in the fall is called a sentence and used as a diuretic or hemostatic agent. Equisetum plants contain a lot of pharmacological ingredients and have antihyperglycemia, diuretic and liver protection. It is used as a skin anti-inflammatory agent in Europe, Asia and the Americas, and as an antibacterial agent in Turkey and the United States. In addition, it has been reported that horsetail extract has glycemic control activity in type 2 insulin-independent diabetes.
흑두(Glycine max (L.) Merrill)는 검은콩을 말하며, 검은콩은 신장계통의 대사 촉진에 좋은 효과를 보인다고 한다. 신장계통이 약한 사람은 몸이 냉하고 신진대사가 원활하지 않아 몸에 여분의 수분이나 지방이 쌓이게 되는 것이다. 검은콩을 먹으면 신장의 작용이 활발해져 수분과 지방이 축적되지 않음으로써 알코올의 대사 및 배설을 촉진시켜 숙취를 예방한다. Glycine max (L.) Merrill refers to black beans, which are said to have a good effect on the metabolism of the kidney system. People with weak kidneys are cold body and metabolism is not smooth, so the body will accumulate extra moisture or fat. When you eat black beans, the kidneys are active and moisture and fat do not accumulate, thereby promoting the metabolism and excretion of alcohol to prevent hangovers.
검은콩의 성분으로는 단백질이 36~45%, 기름이 17~22% 들어 있다. 이 밖에 트리테르페노이드사포닌, 질소화합물, 탄수화물, 사탕, 펙틴, 무기물과 비타민이 있다. 단백질의 80~90%는 필수 아미노산, 즉 아르기닌, 메티오닌, 트레오닌, 류신, 이소류신, 발린 등으로 이루어졌다. Black beans contain 36-45% protein and 17-22% oil. There are also triterpenoids saponins, nitrogen compounds, carbohydrates, candy, pectins, minerals and vitamins. 80-90% of the protein consists of essential amino acids: arginine, methionine, threonine, leucine, isoleucine and valine.
회분에는 K, Mg, Cu, Fe, Mn, Ni, Zn과 흔적의 Co 그리고 인산이 있다. 씨에는 또한 비타민 A, B1, B2, D, E, K와 이소플라본 배당체인 다이아진과 헤니스틴, 로비닌 등이 들어 있다. The ash contains K, Mg, Cu, Fe, Mn, Ni, Zn and trace Co and phosphoric acid. Seeds also contain vitamins A, B 1 , B 2 , D, E, K and isoflavone glycosides such as diazine, heistin, and rovinin.
녹두(Phaseolus aureus, Phaseolus radiatus, Mung bean, Green bean)는 쌍 떡잎식물 장미목 콩과에 속하는 한해살이풀로서, 원산지는 인도로 추정하며 한국, 중국 및 인도 등의 아시아 지역에 주로 분포한다. 녹두는 따뜻한 기후의 양토 (壤土 : 모래와 점토가 알맞게 섞인 검은빛의 흙)에서 잘 자라며 높이는 30-80 cm 정도이다. 줄기는 가늘고 세로로 난 맥이 있고 10여 개의 마디가 있으며 가지를 친다. 잎은 한 쌍의 떡잎과 갓 생겨난 잎이 나온 뒤, 3개의 작은잎으로 된 겹잎이 나온다. 꽃은 노란색으로 8월에 피며 잎겨드랑이에 몇 개씩 모여나나 3-4쌍만이 열매를 맺는다. 열매는 협과로 처음에는 녹색이지만 익으면 검어지고 길고 거친 털로 덮인다. 길이 5-6 cm이고 한 꼬투리에 10-15개의 종자가 들어 있다. 종자는 녹색인 것이 많으나 노란색, 녹색을 띤 갈색, 검은빛을 띤 갈색인 것도 있다. 품종을 나누지 않고 종자의 빛깔에 따라 노란색, 녹색을 띤 갈색, 검은빛을 띤 갈색 녹두로 구분하나 녹색 녹두가 전체의 90%를 차지한다. 성분은 녹말 53-54%, 단백질 25-26%로 영양가가 높고 향미가 좋다. Mung bean (Phaseolus aureus, Phaseolus radiatus, Mung bean, Green bean) is a perennial herb that belongs to the dicotyledonous rosewood legume. Mung beans grow well on warm climate loam (壤土: black soil mixed with sand and clay) and are about 30-80 cm in height. The stem has a thin, vertical vein, about 10 nodes, and branches. The leaves come in pairs of cotyledons and freshly formed leaves, followed by three leaflets. Flowers are yellow and bloom in August, gathering several on axilla, but only 3-4 pairs bear fruit. Fruits are edible, initially green, but ripened and covered with long, coarse fur. It is 5-6 cm long and contains 10-15 seeds in one pod. Seeds are often green, but yellow, greenish brown, and blackish brown. The varieties are divided into yellow, greenish brown, and blackish brown mung beans, depending on the color of the seeds, but green mung beans make up 90% of the total. The ingredients are 53-54% starch and 25-26% protein.
녹두는 동의보감 등의 문헌에 피부 미용 효과를 얻을 수 있다고 기록되어 있으며, 특히 녹두 단백질과 녹두 후라보노이드 성분은 세안에 효과적이며, 생리활성 성분인 비텍신과 이소비텍신은 항산화 효과가 뛰어나 피부노화 방지 효과를 갖는다는 등의 사실이 알려져 있다. Mung beans have been documented to have a skin cosmetic effect, such as Dongbobogam. Mung bean protein and mung bean flavonoids are particularly effective in face washing, while bioactive ingredients, bitexin and isobitexin, have excellent antioxidant effects and prevent skin aging. It is known that such facts.
녹두는 '원기를 보하는데 좋고 오장(五臟)을 조화롭게 하며 정신을 안정시키고 풍을 다스리며 피부를 아름답게 한다'라고 식료본초에 기록되어 있다. 또한 여름을 타는 증세와 식욕부진에 효과적이고 해열, 고혈압, 숙취에 좋으며 잡티제거, 땀띠나 여드름 등 각종 피부질환 및 미백에도 유용하여 생리활성 성분인 비텍신과 이소비텍신은 항산화 효과가 뛰어나 지금도 한방 화장품의 주원료로 쓰이고 있다 Mung bean is written in the medicinal herb, 'It is good for freshness, harmonizes five intestines, stabilizes the mind, controls the wind, and makes the skin beautiful.' In addition, it is effective for summer symptoms and anorexia, and it is good for fever, high blood pressure, hangover, and various skin diseases such as blemishes, sweat bands and acne, and whitening. It is used as main raw material
적소두는 적소두(팥; Phaseolus angularis)는 콩과 식물의 한해살이 풀로서, 이뇨 작용이 있으며 수종을 가라앉히는 데에 민간 요법으로 사용되어 왔다. 이뇨, 거습, 활혈, 배농, 해독 등의 효능이 있어 수종, 각기, 황달, 하리 등의 증상을 치료하기 위해 사용된다. Red bean is red bean (phaseolus angularis) is a perennial plant of legumes, has diuretic effect and has been used as a folk remedy to calm species. Diuretic, moist, bleeding, drainage, detoxification, etc. Efficacy in treating species, each, jaundice, hari, and other symptoms.
지구자(헛개)는 술을 마신 후 나는 여러 질병에 효험이 있는 것으로 늘리 알려져 있고, 해독, 소갈병(당뇨), 치질, 알코올 중독, 황달, 술로 인한 지방간, 황달, 간염, 간경화 등 간질환과 술로 인한 대장, 위, 뇌질환 등에 약효가 있다. 최근 연구결과 헛개나무(Hovenia dulis Thunb) 추출물이 숙취해소 및 간 기능 활성과 보호에 우수한 효과가 있음이 입증되었다. The earth vulgaris (haven) is known to be effective in many diseases after drinking alcohol, and detoxification, sputum (diabetes), hemorrhoids, alcoholism, jaundice, fatty liver caused by alcohol, jaundice, hepatitis, cirrhosis, etc. Due to the large intestine, stomach, brain disease is effective. Recent studies have demonstrated that the extract of Hovenia dulis Thunb has an excellent effect on the hangover and liver function and protection.
헛개나무의 여러 부위 중 간 기능에 대해 보호 효과가 가장 우수한 부위가 열매부위라고 알려져 있다. 헛개나무는 호둘로사이드(Hoduloside)Ⅰ, Ⅱ, Ⅲ, Ⅳ, Ⅴ, 호베닌(Hovenine) A, 호베노락톤(Hovenolactone), 호베노사이드(Hovenoside) D, G, I, 사포닌 C2, E, H, 라마노스, 만노스, 글루코스, 갈락토스, 아라비노스 등의 성분으로 구성되어 있다. 이러한 성분들에는 인체에 유익한 물질들이 함유되어 있어 술 해독작용과 피로회복, 당뇨병, 구토증, 소화불량, 액취증의 치료 및 여러 가지 질병의 치료효과를 가지고 있는 것으로 판명되고 있다. Among the various parts of the bark tree, the most effective part of protection against liver function is known as the fruit part. Hollow trees include Hoduloside I, II, III, IV, V, Hovenine A, Hovenolactone, Hovenoside D, G, I, Saponin C2, E, It consists of components, such as H, lamanose, mannose, glucose, galactose, and arabinose. These ingredients contain substances that are beneficial to the human body and have been found to have the effects of alcohol detoxification, fatigue recovery, diabetes, nausea, indigestion, intoxication, and various diseases.
지구자에는 간의 알코올 분해를 촉진하여 아세트알데히드의 분해시키는 호베노둘리놀(Hovenodulinol) 및 간의 기능을 향상시키는 페루릭산(Feluric acid) 등이 함유되어 있으며 음주 후 숙취을 해소하는데 효과적이다 Earth's Earth contains Hovenodulinol, which accelerates alcohol breakdown and decomposes acetaldehyde, and Ferulric acid, which improves liver function.
중국 명나라 때 이시진이 쓴 본초강목(本草綱目)에는 "헛개나무는 가을이 되면 열매 대궁이 비대해지면서 산호 모양으로 되는데, 이것을 약으로 쓰며 맛이 달아서 사람들이 먹는다. 열매에는 숙취를 덜게 하고 간을 보호해 주는 약효가 있다"고 기록되어 있다. 헛개나무는 글루타메이트(glutamate)로 유도한 뇌 손상을 억제하는 효과가 있는 것으로 보고되었다. 헛개나무는 사염화탄소로 유도한 간 소상을 억제하는 효과를 가지며(Hase K et al., Biol. Pharm. Bull. 20(4):381-385, 1997), 헛개나무 열매에서 분리한 디하이드로플라보놀(dihydroflavonols), 호베니틴(hovenitins) I, II 및 III가 알코올로 인한 간 손상을 억제하는 효과가 있다고 보고되었다(Yoshikawa M et al., Yakugaku Zasshi 117(2):108-118, 1997). 헛개나무 열매에서 분리한 석탄산 화합물(phenolic compound)에는 글루타메이트(glutamate)로 유도한 뇌손상을 억제하는 효과가 있으며(Li G et al., Arch. Pharm. Res. 28(7):804-809, 2005), 헛개나무 열매는 급성 알코올 투여시 알코올 분해를 촉진시키는 효과가 있음이 보고되었다(Ji Y. et al., Zhong Yao Cai 24(2):126-128, 2001). In the Ming Dynasty, the Sichuan River, written by Yi Shijin, said, "In autumn, the bark tree grows in the shape of a coral, and the fruit becomes large. It is used as a medicine and tastes sweet so that people eat it. It protects you. " It has been reported that hawthorn has the effect of inhibiting glutamate-induced brain damage. Hazel tree has the effect of inhibiting carbon tetrachloride-induced liver injury (Hase K et al., Biol. Pharm. Bull. 20 (4): 381-385, 1997), and dihydroflavonol isolated from the fruit of Hazel tree (dihydroflavonols), hovenitins I, II and III have been reported to have the effect of inhibiting alcohol-induced liver damage (Yoshikawa M et al., Yakugaku Zasshi 117 (2): 108-118, 1997). Phenolic compounds isolated from the fruit of the bark have the effect of inhibiting glutamate-induced brain damage (Li G et al., Arch. Pharm. Res. 28 (7): 804-809, (2005), it has been reported that barberry fruit has an effect of promoting alcohol degradation upon acute alcohol administration (Ji Y. et al., Zhong Yao Cai 24 (2): 126-128, 2001).
헛개나무열매, 잎, 가지에서 포도당, 사과산, 칼슘, 후랑구라닌, 호베닌, 호베노시드, 하벤산등 인체내의 유익한 성분을 함유하고 있어서 술 해독작용, 피로회복에 좋은 것으로 알려져 있으며, 열매, 잎, 줄기, 뿌리를 약재로 사용하는 것으로 알려져 있다(정보섭 및 신민교, 향약대사전, 영림사, pp 291-292, 1998). It is known to be good for alcohol detoxification and fatigue recovery because it contains beneficial ingredients such as glucose, malic acid, calcium, furanguranine, hobenin, hobenoside, and habenic acid in the bark fruit, leaves and branches. It is known to use leaves, stems, and roots as medicinal herbs (Information and Shinmingyo, Hyangjedae, Yeonglimsa, pp 291-292, 1998).
갈근(Pueraria lobata Ohwi)은 콩과(Leguminosae)로 칡(Pueraria lobata OHWI)의 주피를 제거한 뿌리이다. 갈근에는 이소플라보노이드(isoflavonoids)로 다 이자인(daidzein), 다이진(daidzin), 포모네팀 제니스틴(formonetinm genistein) 등이 함유되어 있다. 또한 트리테르펜(triterpenoids)인 소야사포제놀(soyasapogenol) A와 쿠주사포제놀(Kuzusapogenol) B 등이 함유되어 있다. 이러한 성분은 진정 작용, 하열 작용 및 혈관의 이완 작용을 하는 것으로 알려져 있다. 갈근은 알코올로 인한 지방간의 생성을 억제하는 약제 중의 하나로(Kwon HJ et al., World J. Gastroenterol. 11(35): 5512-5516, 2005), 갈근 뿌리의 물 추출물은 알코올 투여로 인한 지방 대사와 항산화 효소의 장애를 제거하는 역할을 한다(Lee JS. et al., Clin. Chim. Acta. 347(1-2):121-128, 2004). 갈근에 함유된 이소플라보노이드(isoflavonoids) 중 하나인 다이진(daidzin)은 알코올의 투여 후 혈중 알코올의 농도를 낮추는 효과가 있으며(Xie CI et al., Alcohol Clin. Exp. Res. 18(6):1443-1447, 1994) 또한 갈근은 인산과 함께 알코올 섭취를 억제시키는 효과가 있다(Carai MA et al., Fitoterapia Aug;71 Suppl 1:S38-42, 2000). Brown root (Pueraria lobata Ohwi) is a legume (Leguminosae), the roots of the bark of Pueraria lobata OHWI. The root roots are isoflavonoids, which include dizezein, daidzin, and formonetinm genistein. It also contains triterpenoids, soyasapogenol A and kuzusapogenol B. These ingredients are known to have a sedative, hypothermic and vascular relaxing effect. Reed root is one of the drugs that inhibit the production of fatty liver due to alcohol (Kwon HJ et al., World J. Gastroenterol. 11 (35): 5512-5516, 2005). And remove the disorder of antioxidant enzymes (Lee JS. Et al., Clin. Chim. Acta. 347 (1-2): 121-128, 2004). Diazine, one of the isoflavonoids contained in the roots, has the effect of lowering the concentration of alcohol in the blood after the administration of alcohol (Xie CI et al., Alcohol Clin.Exp. Res. 18 (6): 1443-1447, 1994) Also, root canal has an inhibitory effect on alcohol consumption with phosphoric acid (Carai MA et al., Fitoterapia Aug; 71 Suppl 1: S38-42, 2000).
진피는 귤(Citrus unshiu Markovich) 또는 그의 근연식물(산초나무과 Rutaceae)의 성숙한 과피이다. 정유성분인 d-리모넨(d-limonene), 리나롤(linalool)과 리날리아세테이트(linalylacetate)가 함유되어 있고, 플라보노이드(flavonoids)인 헤스피리딘(hesperidin), 나린긴(naringin), 포시린(porcirin)과 노비레틴(nobiletin)이 함유되어 있고 알카로이드(alkaloid)인 시네프린(synephrine) 또한 함유되어 있다. 이러한 진피는 항알레르기 활성(antiallergic activity)이 있고 진정 효과, 항바이러스 효과와 세로토닌(serotonine)의 작용도 향상시킨다는 보고도 있다. 연구자들은 갈근과 진피가 함유된 한약처방이 알코올의 흡수를 저하시켜 음주 후 혈청 알코올의 농도를 저하시켰다고 보고하였고(Shin BS et al., J. Toxicol. Environ. Health A. 68(23-24):2219-2226, 2005), 진피가 C형 감염(hepatitis C)에서 간의 손상을 최소화하는 효과가 있다고 보고되었다(Cyong JC et al., Am. J. Chin. Med. 28(3-4):351-360, 2000). The dermis is the mature rind of the tangerine (Citrus unshiu Markovich) or its plant (Riaceae). Contains essential oils such as d-limonene, linalool and linalilacetate, and flavonoids hesperidin, naringin and porcirin ) And nobiletin and alkaloid synephrine. These dermis have antiallergic activity and have been reported to improve sedative, antiviral and serotonin action. The researchers reported that Chinese herbal prescription containing root and dermis lowered alcohol absorption and decreased serum alcohol concentration after drinking alcohol (Shin BS et al., J. Toxicol. Environ. Health A. 68 (23-24) : 2219-2226, 2005), it has been reported that dermis has the effect of minimizing liver damage in hepatitis C (Cyong JC et al., Am. J. Chin.Med. 28 (3-4): 351-360, 2000).
갈화(葛花, Pueraria thunbergiana)는 칡의 꽃을 말하는 것으로, 주독을 해소하고 장의 독을 제거해 주는 약재이다. 상주(傷酒)에 의한 발열, 악심, 식욕부진 및 지혈(止血)등에 효과가 있다(정 보섭 및 신 민교, 향약대사전, 영림사, pp704-705, 1998). Galhwa (葛花, Pueraria thunbergiana) refers to the flower of the ,, a medicine that relieves the poison and removes the intestinal poison. It is effective in fever, ill feeling, loss of appetite and hemostasis caused by resident wine (Jebo Bo-seop and Shin Mingyo, Hyangjeomsa, Yeonglimsa, pp704-705, 1998).
대두황권 (大豆黃卷, leguminosae)은 콩과에 속하는 1년생 본초인 검정콩을 발아한 것으로, 일반적으로 콩나물을 말한다. 콩나물은 콩을 발아시켜 만든 식품이지만 오히려 콩을 섭취하는 것보다 훨씬 우리 몸에 좋아 각종 성인병을 예방하고 치료하는 효과를 지니고 있다. 콩나물에서 주목할 만한 점은 콩에는 없는 비타민 C와 비타민 B2, 나이신과 비타민 K가 생성된다는 것이다. 그 외에도 칼륨과 칼슘 등의 미네랄과 식이섬유도 다량 함유하고 있어 북유럽에서는 콩나물이 귀중한 비타민 및 미네랄원으로 높이 평가되고 있다. 콩 자체의 소화 흡수율은 낮으나, 대두 콩나물은 아밀라아제 (amylase), 인베르타아제 (invertase) 등의 소화효소를 가지고 있어 소화 흡수율이 높고, 식물성 단백질로서 리진, 트립토판, 메치오닌 등의 필수 아미노산을 포함하고 있다. Soybean hwangwon (大豆 黃 卷, leguminosae) is a soybean sprout, a year-old herb that belongs to the legumes, usually refers to bean sprouts. Sprouts are foods made by germinating soybeans, but they are much better for our bodies than eating soybeans, and have the effect of preventing and treating various adult diseases. What's noteworthy about soybean sprouts is the production of vitamin C and vitamin B2, nisin and vitamin K, which are not found in soybean sprouts. In addition, it contains high amounts of minerals such as potassium and calcium and dietary fiber, so bean sprouts are highly regarded as a valuable source of vitamins and minerals. Soybean sprouts have a low digestive absorption rate, but soybean sprouts have digestive enzymes such as amylase and invertase, and thus have high digestive absorption rates, and are plant proteins containing essential amino acids such as lysine, tryptophan, and methionine. .
대두황권은 콩나물용 국산 황대두를 하루 정도 물에 불려서 발아시킨 후 상온에서 5일 정도 키운 콩나물을 서늘한 곳에서 바짝 건조시켜서 약재로 이용한다. 대두황권은 정신적, 육체적 활력을 불어 넣으며, 숙취해소 효과 및 감기로 인한 두동, 복통, 설사, 피부병 등을 치료한다. Soybean yellow soybeans are soaked in soybean sprouts for about a day, germinated, and then dried for 5 days at room temperature in a cool place. The soybean yellow area gives mental and physical vitality, and it cures hangover, abdominal pain, diarrhea and skin disease caused by hangover effect and cold.
본 발명의 숙취 해소용 조성물은 동물 실험 결과뿐 아니라 인체 실험에서도 짧은 시간 내에 혈중 알코올 농도를 현저하게 감소시키는 효과를 갖는다. 이와 같이 신속한 혈중 알코올 농도 감소는 알코올 대사 속도가 빠르다는 것을 나타내는 것이고, 이는 독성 물질로서 작용하는 알코올 대사 중간 산물인 아세트알데히드의 체내 잔류 시간이 단축됨을 의미하는 것이므로, 아세트알데히드로 인한 숙취를 해소하는데 우수한 효과를 갖는다는 것을 확인할 수 있다. Hangover composition of the present invention has the effect of significantly reducing blood alcohol concentration within a short time not only in animal experiments but also in human experiments. This rapid decrease in blood alcohol levels indicates a rapid rate of alcohol metabolism, which means that the residence time of acetaldehyde, an alcohol metabolite intermediate, acting as a toxic substance is shortened. It can be confirmed that it has an excellent effect.
동물 실험 및 인체 실험에서 확인되는 바와 같이, 상기와 같은 본 발명의 조성물의 알코올 농도 감소 및 숙취 해소 효과는 알코올에 의한 추출에 의하여 제조된 경우와 열수에 의한 추출에 의하여 제조된 경우 모두에서 얻을 수 있다. As can be seen in animal experiments and human experiments, the alcohol concentration reduction and hangover relieving effects of the compositions of the present invention can be obtained both in the case of extraction by alcohol and in case of extraction by hot water. have.
즉, 본 발명에 따른 천연물 조성물은 기초 약재를 원료로 하여 그 제조 방법이 용이하며, 동물 실험 및 인체 시험에서 입증된 바와 같이 기존의 제품보다 월등한 숙취 해소 효능을 보이는 것이다.That is, the natural product composition according to the present invention is easy to manufacture the method using the basic medicine as a raw material, and shows a superior hangover resolution effect than conventional products as demonstrated in animal experiments and human tests.
이하, 본 발명을 하기의 실시예에 의해서 상세히 설명할 것이나, 이들 실시예는 본 발명을 예시하기 위한 것일 뿐이며, 본 발명의 범위가 이들 실시예에 의하여 한정되는 것은 아니다. Hereinafter, the present invention will be described in detail by the following examples, but these examples are only for illustrating the present invention, and the scope of the present invention is not limited to these examples.
본 실시예에서 사용된 원료 약재의 조성비를 아래의 표 1에 나타내었다. The composition ratio of the raw material medicines used in this example is shown in Table 1 below.
[표 1]TABLE 1
실시예 1: 천연 추출물을 함유하는 조성물의 제조-Example 1: Preparation of Compositions Containing Natural Extracts- 액제Liquid
(1) 알코올 추출물 A 제조(1) Alcohol Extract A Preparation
상기의 표 1에 기재된 종류 중에서, 이온화칼슘 시비 현미, 쇠뜨기, 흑두, 녹두, 적소두, 지구자, 갈근, 감초, 진피, 대추, 칼슘 화합물 의 천연 약재를 준비하여, 식물 전체, 잎 또는 열매를 깨끗이 세척하고 잘게 절단한 후, 표 1에 기재된 중량비로 혼합한 후, 상기 혼합물에 75% 에탄올을 중량 기준으로 3배의 양으로 가하여 둥근 바닥 플라스크에서 80℃에서 4시간 동안 환류 냉각기(reflux condenser)를 부착하여 가열 및 환류시켜 추출하였다. Among the kinds shown in Table 1 above, natural medicinal herbs such as calcium fertilized brown rice, horseradish, black bean, mung bean, red bean bean, earthworm, brown root, licorice, dermis, jujube, calcium compound are prepared to clean the whole plant, leaves or fruits After washing and chopping, the mixture was mixed at the weight ratios shown in Table 1, and then the reflux condenser was added to the mixture in an amount of 3 times by weight in a round bottom flask at 80 ° C. for 4 hours. Attached, heated and refluxed.
얻어진 추출물을 냉각시키지 않고 뜨거운 상태에서 여과지(Whatman사 제조 No. 1001100) 또는 통상의 여과 장치에 통과시켜 고형분을 제거하였다. 걸러진 여과액을 회전식 증발 건조기 또는 통상의 농축기를 사용하여 감압 건조시켜 최종 추출물을 제조하였다. The obtained extract was passed through a filter paper (No. 1001100 manufactured by Whatman) or a conventional filtration apparatus in a hot state without cooling to remove solids. The filtered filtrate was dried under reduced pressure using a rotary evaporator or a conventional concentrator to prepare a final extract.
(2) 알코올 추출물 B 제조(2) Alcohol Extract B Preparation
상기의 표 1에 기재된 종류 중에서 갈화, 미나리, 무우, 콩나물(대두황권), 생강의 천연 약재를 준비하여, 식물 전체, 잎 또는 열매를 깨끗이 세척하고 잘게 절단한 후, 표 1에 기재된 중량비로 혼합한 후, 상기 혼합물에 75% 에탄올을 중량 기준으로 3배의 양으로 가하여 둥근 바닥 플라스크에서 80℃ 에서 20분 동안 환류 냉각기(reflux condenser)를 부착하여 가열 및 환류시켜 추출하였다. Of the kinds shown in Table 1 above, natural herbs such as brown, buttercup, radish, bean sprouts (soybean sprouts) and ginger are prepared, the entire plant, leaves or berries are thoroughly washed and finely cut, and then mixed in the weight ratio shown in Table 1 Thereafter, 75% ethanol was added to the mixture in an amount of 3 times by weight, followed by heating and refluxing by attaching a reflux condenser at 80 ° C. for 20 minutes in a round bottom flask.
얻어진 추출물을 냉각시키지 않고 뜨거운 상태에서 여과지(Whatman사 제조 No. 1001100) 또는 통상의 여과 장치에 통과시켜 고형분을 제거하였다. 걸러진 여과액을 회전식 증발 건조기 또는 통상의 농축기를 사용하여 감압 건조시켜 최종 추출물을 제조하였다.The obtained extract was passed through a filter paper (No. 1001100 manufactured by Whatman) or a conventional filtration apparatus in a hot state without cooling to remove solids. The filtered filtrate was dried under reduced pressure using a rotary evaporator or a conventional concentrator to prepare a final extract.
(3) (3) 열수Hydrothermal 추출물 A 제조 Extract A manufacture
상기 표 1에 기재된 종류의 약재 중에서 이온화칼슘 시비 현미, 쇠뜨기, 흑두, 녹두, 적소두, 지구자, 갈근, 감초, 진피, 대추, 칼슘 화합물를 준비하고, 표 1에 기재된 중량비로 혼합한 후, 얻어진 약재 혼합물을 상기 혼합물 중량의 3배의 양의 물에 넣어, 100℃에서 240분 동안 1차 추출 및 여과하여 1차 추출물을 얻고, 남은 고형분에 상기 고형분 중량의 1/2의 새로운 물을 추가하여 100℃에서 4시간 동안 환류 냉각기(reflux condenser)를 부착하여 가열 및 환류시켜 2차 추출하여 2차 추출물을 얻었다. Among the medicinal herbs of the kind described in Table 1, ionized calcium fertilized brown rice, horseradish, black bean, mung bean, red bean sprout, earth flakes, brown root, licorice, dermis, jujube, calcium compound, prepared and mixed in the weight ratio shown in Table 1, The mixture was poured into an amount of water three times the weight of the mixture, followed by primary extraction and filtration at 100 ° C. for 240 minutes to obtain a primary extract, and by adding fresh water 1/2 of the weight of the solid to the remaining solid. A reflux condenser was attached at 4 ° C. for 4 hours, heated and refluxed to obtain a second extract.
상기 1차 추출물 및 2차 추출물을 여과하여 고형분를 제거한 후, 여과액을 가열 농축하였다. After filtering the primary extract and the secondary extract to remove solids, the filtrate was concentrated by heating.
(4) (4) 열수Hydrothermal 추출물 B 제조 Extract B manufacturer
상기 표 1에 기재된 종류의 약재 중에서 갈화, 미나리, 무우, 콩나물(대두황권), 생강을 준비하고, 표 1에 기재된 중량비로 혼합한 후, 얻어진 약재 혼합물을 상기 혼합물 중량의 3배의 양의 물에 넣어, 내지 100℃에서 20분 동안 1차 추출 및 여과하여 1차 추출물을 얻고, 남은 고형분에 상기 고형분 중량의 1/2의 물을 물을 추가하여 100℃에서 20분 동안 환류 냉각기(reflux condenser)를 부착하여 가열 및 환류시켜 2차 추출하여 2차 추출물을 얻었다. Among the medicinal herbs of the type described in Table 1, browning, buttercups, radishes, bean sprouts (soybean rhubarb) and ginger are prepared and mixed in a weight ratio shown in Table 1, and then the obtained medicinal mixture is three times the amount of water in the mixture. Primary extract and filtered for 20 minutes at 100 ℃ to obtain a primary extract, the water of the solid weight 1/2 of the weight of the solid to the remaining solids at 100 ℃ 20 minutes reflux condenser (reflux condenser ) Was attached, heated and refluxed to obtain a second extract.
상기 1차 추출물 및 2차 추출물을 여과하여 고형분를 제거 한 후, 여과액을 가열 농축하였다. After filtering the primary extract and the secondary extract to remove the solids, the filtrate was concentrated by heating.
(5) 최종 조성물의 제조(5) Preparation of Final Composition
상기 표1의 천연 약재 혼합물 총 25 kg을 알코올 추출 및 감압하여 5.0kg의 농축 추출물을 얻었다(알코올 추출물 A +알코올 추출물 B). A total of 25 kg of the natural herbal mixture of Table 1 was extracted with alcohol and reduced pressure to obtain a concentrated extract of 5.0 kg (alcohol extract A + alcohol extract B).
상기 표1의 천연 약재 혼합물 총 25 kg을 열수 추출 및 감압하여 5.4kg의 농축 추출물을 얻었다(열수 추출물 A +열수 추출물 B). A total of 25 kg of the natural medicinal herb mixture of Table 1 was extracted with hot water and reduced pressure to obtain a concentrated extract of 5.4 kg (hot water extract A + hot water extract B).
상기에서 얻어진 알코올 추출물 5g 혹은 열수 추출물 5g에 각각 20중량%의 설탕 혹은 포도당과, 3.5중량%의 말레인산과 젖산, 3.5중량%의 페룰산, 타우린, 베타인을 첨가하고 15배 부피의 증류수를 혼합하여 1회 투여 분량의 액상의 조성물을 제조하였다.To 5 g of the alcohol extract or 5 g of hydrothermal extract obtained above, 20% by weight of sugar or glucose, 3.5% by weight of maleic acid and lactic acid, 3.5% by weight of ferulic acid, taurine and betaine were added, and 15 times volume of distilled water was mixed. A single dose of liquid composition was prepared.
실시예 2: 천연 추출물을 함유하는 조성물의 제조-Example 2: Preparation of Compositions Containing Natural Extracts- 환제Pill
상기 표1 의 조성비율로 원료를 구입하여 통상의 방법으로 분말화하고 20중 량%의 벌꿀을 첨가하여 환으로 제조하였다. 이때 1회 투여량은 25g으로 제조하였다.The raw materials were purchased at the composition ratios of Table 1, and powdered by a conventional method, and 20% by weight of honey was added to prepare a ring. At this time, the single dose was prepared in 25g.
실시예 3: 알코올 배설 촉진 및 아세트알데히드 분해 촉진 효능 확인을 위한 동물 시험 Example 3: Animal Testing to Confirm Efficacy in Accelerating Alcohol Excretion and Accelerating Acetaldehyde Degradation
(1) 시험군 설정(1) Test group setting
상기의 실시예 1에서 제조된 조성물의 알코올 배설 촉진 효능을 확인하기 위하여, 동물에서의 상기 조성물의 혈중 알코올 농도 감소 효과를 시험하였다. In order to confirm the alcohol excretion promoting effect of the composition prepared in Example 1 above, the effect of reducing the blood alcohol concentration of the composition in the animal was tested.
9주령의 스프라그-돌리(Sprague-Dawley) 랫트 수컷 30마리(체중 280-320 g)를 7일 동안 온도 21±3℃, 상대습도 50±5%, 조도 200-300 룩스 조건의 실험실에 적응시킨 후, 건강한 동물 10 마리들만을 선택하여 시험에 사용하였다. 음용수로는 증류수를 자유 섭취시켰고 사료로는 실험 동물용 사료를 자유 섭취시켰다. 적응 기간 중 건강에 이상이 없는 개체들의 체중을 측정한 후, 평균 체중에 가까운 동물 10마리를 선택하였다. 이렇게 선택된 동물을 무작위 선택 방법으로 5마리씩 2 개의 군으로 분배하였고, 제1군은 음성 대조군으로 증류수만을 투여하였고, 제2군은 시험군으로 본 발명의 실시예 1에서 제조된 최종 조성물(알코올 추출물 5g 에 각각 20중량%의 설탕과, 3.5중량%의 말레인산, 각각 1.2중량%의 페룰산, 타우린, 베타인을 첨가하고 15배 부피의 증류수를 혼합한 1회 투여 분량의 액상의 조성물)을 투여하였다.30 male Sprague-Dawley rats (weight 280-320 g) of 9 weeks of age were adapted to the laboratory for 7 days at a temperature of 21 ± 3 ° C, 50 ± 5% relative humidity, and a roughness of 200-300 lux. Only 10 healthy animals were selected and used for testing. Distilled water was freely consumed as drinking water and experimental animal feed was freely consumed. After weighing the subjects who had no health problems during the adaptation period, 10 animals near the mean weight were selected. Thus selected animals were divided into two groups of five by random selection method, the first group was administered only distilled water as a negative control group, the second group was the final composition prepared in Example 1 of the present invention (alcohol extract) 5 g of 20% by weight of sugar, 3.5% by weight of maleic acid, 1.2% by weight of ferulic acid, taurine, and betaine, respectively, were added in a single dose of liquid composition containing 15 volumes of distilled water). .
(2)조성물 및 에탄올 투여(2) Composition and ethanol administration
음성 대조군인 제1군에는 증류수 4g/kg을 주사기를 사용하여 경구 투여 방법 으로 존데를 사용하여 랫트의 위내에 주입하였다. 양성 대조군인 제2군 에는 본 발명의 실시예 1의 최종조성물 중 알코올 추출물을 사용한 조성물(알코올 추출물 5g 에 각각 20중량%의 설탕과, 3.5중량%의 말레인산, 각각 1.2중량%의 페룰산, 타우린, 베타인을 첨가하고 15배 부피의 증류수를 혼합한 1회 투여 분량의 액상의 조성물)을 4g/kg의 양으로 경구 투여 하였다. 상기와 같은 증류수 및 본 발명 조성물 투여 후, 15분 후에, 30% 에탄올 용액을 5.0g/kg을 경구 투여하고, 1시간, 2시간 후의 피험체의 혈중 에탄올 농도를 측정하였다.In the first group, the negative control group, 4 g / kg of distilled water was injected into the stomach of rats using sonde by the oral administration method using a syringe. The second group, which is a positive control group, includes a composition using an alcohol extract in the final composition of Example 1 of the present invention (5 g of alcohol extract, 20 wt% sugar, 3.5 wt% maleic acid, 1.2 wt% ferulic acid, and taurine, respectively). , Betaine was added and 15 times the volume of distilled water mixed with a single dose of liquid composition) orally administered in an amount of 4g / kg. After administration of distilled water and the composition of the present invention as described above, 15 minutes, 5.0 g / kg of a 30% ethanol solution was orally administered, and blood ethanol concentration of the subject was measured after 1 hour and 2 hours.
(3)혈중 에탄올 농도의 측정(3) Measurement of blood ethanol concentration
30 % 에탄올 용액 5.0g/kg을 경구 투여한 후, 1시간, 2시간 후에, 동물을 에틸 에테르로 순간 마취 시킨 후 심장에 주사 바늘을 꽂아 채혈하는 방법으로 혈액을 각각 3ml식 채혈한 후, EDTA 가 들어 있는 밀봉 튜브에 넣어 냉장한 후 서울 의과학 연구소(SCL Lab)에서 혈중 알코올 농도를 측정하였다.After oral administration of 30 g of ethanol solution 5.0 g / kg, 1 hour, 2 hours, the animals were anesthetized with ethyl ether, and the blood was collected by inserting a needle into the heart. After refrigerated in a sealed tube containing the blood alcohol concentration was measured at the Seoul Medical Research Institute (SCL Lab).
검사방법은 효소법(Enzymatic assay)으로서 검사원리는 다음 반응식과 같이 NAD와ADH(알코올 탈수소효소)를 이용한다. The test method is an enzymatic assay, which uses NAD and AH (alcohol dehydrogenase) as shown in the following scheme.
NADH의 형성은 378nm에서 흡광도 증가로 정량할 수 있다. 이때, 1,3-디아미노-2-하이드록시프로판이 알데하이드를 포획하는 시약이며, 효과적인 완충액으로 작용한다. 이러한 시약계는 알코올 탈수소효소를 이용하는 에탄올 정량법으로 다른 검사방법에 비해 안정성이 있다. Formation of NADH can be quantified by increased absorbance at 378 nm. At this time, 1,3-diamino-2-hydroxypropane is a reagent for trapping aldehyde, and serves as an effective buffer. This reagent system is ethanol quantitative determination using alcohol dehydrogenase is more stable than other test methods.
상기의 측정 결과를 다음의 표 2 및 도 2에 나타내었다. 표 2는 동물 실험 결과 조성물을 비복용한 쥐와 복용한 쥐의 혈중 알코올 농도를 나타낸 것이며, 각 군의 흰쥐 5 마리에서 얻은 측정치를 평균하여 기재하였다. The measurement results are shown in Table 2 and FIG. 2. Table 2 shows the blood alcohol concentrations of the rats in which the composition was not ingested and the rats in which the composition was obtained, and the averages of the measurements obtained in the five rats of each group were described.
[표 2]TABLE 2
조성물 비복용First group
Non-dosing composition
조성물 복용2nd group
Taking composition
표 2의 결과를 살펴보면 음주 1 시간 후에 본 발명 조성물 복용군은 비복용군에 비하여 66.7 % 혈중 알코올 농도 감소가 측정되었고, 음주 2시간 후에는 93.3 % 감소로 거의 알코올이 모두 대사 된 결과를 보여준다.Looking at the results of Table 2, after 1 hour drinking alcohol, the group taking the composition of the present invention was measured 66.7% decrease in blood alcohol concentration compared to the non-dosing group, after 2 hours drinking 93.3% decrease shows that almost all alcohol is metabolized.
이는 동물에서 본 발명 조성물의 뚜렷한 알코올 배설 촉진 효능을 나타내는 것이다.This is indicative of the apparent alcohol excretion promoting efficacy of the composition of the present invention in animals.
또한, 본 발명의 숙취 해소용 조성물의 급성 독성 평가를 위하여, 상기의 실시예 1에서 제조한 조성물(알코올추출 혹은 열수 추출물 5g 에 각각 20중량%의 설탕과, 3.5중량%의 말레인산, 각각 1.2중량%의 페룰산, 타우린, 베타인을 첨가하고 15배 부피의 증류수를 혼합한 1회 투여 분량의 액상의 조성물)를 사용하여 ICR 마우스에서 경구로 투여하여50% 치사량(LD50)을 측정한 결과, 그 수치가 5g/kg(체중) 이상으로 나타났으며, 이러한 결과에 의하여 본 발명의 조성물이 매우 안전하다는 것을 확인 할 수 있다.In addition, in order to evaluate the acute toxicity of the composition for relieving hangover of the present invention, the composition prepared in Example 1 (alcohol extract or hot water extract 5g each 20% by weight of sugar, 3.5% by weight of maleic acid, 1.2% each 50% lethal dose (LD 50 ) was determined by oral administration in an ICR mouse using a single dose of a liquid composition containing% ferulic acid, taurine, and betaine and mixed with 15 times the volume of distilled water. The value was found to be more than 5g / kg (body weight), it can be confirmed that the composition of the present invention is very safe by this result.
실시예 4: 알코올 배설 및 아세트 알데히드대사 촉진 효능 확인을 위한 인체 시험 Example 4 Human Test for Confirmation of Alcohol Excretion and Acetaldehyde Metabolism Promoting Efficacy
본 발명의 조성물의 인체에서의 알코올 배설 및 대사 촉진 효능을 확인하기 위하여, 건강한 성인 남성 30명을 대상으로 에탄올 섭취 후의 에탄올 농도를 측정하고 음주 다음날에 나타나는 증상(숙취)을 관찰하였다.In order to confirm the effects of alcohol excretion and metabolism promotion in the human body of the composition of the present invention, 30 healthy adult males were measured for ethanol concentration after ethanol ingestion and observed symptoms (hangover) appearing the day after drinking.
1) 인체 시험 대상 1) human subjects
남 30명 30 male
2) 에탄올 농도 측정 기기2) Ethanol concentration measuring instrument
Digital Alcohol Detector CA 2000 (TNT 테크사 제품) Digital Alcohol Detector CA 2000 (manufactured by TNT Tech)
3) 시험 방법3) test method
건강한 성인 남성 30명을 첫날 본 발명 조성물을 투여 하지 않고 음주 하게 한 후 음주 시작 45분 후에 알코올 측정기로 1차 호흡기 알코올 농도를 측정하고, 음주를 계속하여 음주 시작 120분 후 알코올 측정기로 다시 2차 측정하였다.30 healthy adult males were allowed to drink without administration of the present invention on the first day, and after 45 minutes of alcohol initiation, the first respiratory alcohol concentration was measured with an alcohol meter, and the alcohol was continued for 2 minutes after 120 minutes of alcohol consumption. Measured.
일주일 후 동일한 피험자를 대상으로 음주 시작 15분 전에 본 발명 조성물을 투여하게 한 후, 상기 방법과 동일하게 음주 측정을 하였다.One week later, the same subject was administered 15 minutes before the start of drinking, and the alcohol was measured in the same manner as the above method.
성인 남성 1 인당 복용량은 본 발명의 조성물의 경우에는 100ml (알코올 추출물 5g 에 각각 20중량%의 설탕과, 3.5중량%의 말레인산, 각각 1.2중량%의 페룰산, 타우린, 베타인을 첨가하고 15배 부피의 증류수를 혼합한 1회 투여 분량의 액상의 조성물)으로 하였다. 음주 시작 후 45 분, 120분 후의 시점에서 음주 측정기 CA 2000을 사용하여 호흡 중 알코올 농도를 측정하였다. 주종은 소주로 하였고 안주는 삼겹살을 제공하였다. The dose per adult male was 100 ml for each composition of the present invention (5 g of alcohol extract, 20 wt% sugar, 3.5 wt% maleic acid, 1.2 wt% ferulic acid, taurine and betaine, respectively, and 15-fold volume Liquid composition of a single dose amount mixed with distilled water). At 45 and 120 minutes after the start of drinking, breathing alcohol concentration was measured using a breathalyzer CA 2000. Jujong was made with soju and snacks served with pork belly.
하기 표 3과 표 4는 각각 음주 후 45분과 120분이 경과된 후의 각 군별 24인의 평균 혈중 알코올 농도를 나타낸 것이다. Table 3 and Table 4 show the average blood alcohol concentrations of 24 people in each group after 45 minutes and 120 minutes after drinking, respectively.
[표 3][Table 3]
음주 후 45분 경과45 minutes after drinking
[표 4][Table 4]
음주 후 120분 경과120 minutes after drinking
상기한 표 3과 4의 결과를 정리한 결과값을 표 5와 도 3에 나타내었다.Table 5 and FIG. 3 show the results of summarizing the results of Tables 3 and 4.
[표 5]TABLE 5
표 5에서 알 수 있는 바와 같이, 본 발명에 따른 숙취 해소용 조성물의 임상 시험 결과를 살펴보면 음주 45분 후에 본 발명 조성물 복용군은 비복용군에 비하여 42.4% 혈중 알코올 농도 감소가 측정되었고, 음주 2시간 후에는 49.5% 감소로 두 경우 모두 비복용군에 비하여 거의 2배의 알코올이 모두 배출된 결과를 보여준다. As can be seen in Table 5, looking at the clinical trial results of the hangover relief composition according to the present invention 45 minutes after drinking the composition of the present invention group was measured 42.4% blood alcohol decrease compared to the non-dose group, drinking 2 After time, a 49.5% reduction resulted in nearly twice as much alcohol release as both groups.
이는 동물에서 본 발명 조성물의 뚜렷한 알코올 배설 촉진 효능과 매우 일치하는 결과, 즉 시간이 경과 할수록 본 발명 주성물의 효능이 증가한다는 사실을 나 타내는 것이다.This indicates a result that is very consistent with the apparent alcohol excretion promoting efficacy of the composition of the present invention in animals, i.e., the efficacy of the main product of the present invention increases with time.
도 1은 해당 글루코스 대사 경로를 나타낸 순서도.1 is a flow chart showing the glucose metabolism pathway.
도 2는 본 발명의 조성물의 알코올 대사 촉진 효과를 알아보기 위한 동물 실험 결과 그래프.Figure 2 is a graph of animal experiments to determine the effect of promoting alcohol metabolism of the composition of the present invention.
도 3은 본 발명의 조성물의 알코올 대사 촉진 효과를 알아보기 위한 인체 실험 결과 그래프.Figure 3 is a human experiment result graph to determine the alcohol metabolism promoting effect of the composition of the present invention.
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080109116A KR101068128B1 (en) | 2008-11-04 | 2008-11-04 | Natural product composition containing ionized calcium fertilized unmilled rice for activating alcohol excretion,aldehyde metabolism and curing a hangover and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080109116A KR101068128B1 (en) | 2008-11-04 | 2008-11-04 | Natural product composition containing ionized calcium fertilized unmilled rice for activating alcohol excretion,aldehyde metabolism and curing a hangover and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20100050032A KR20100050032A (en) | 2010-05-13 |
KR101068128B1 true KR101068128B1 (en) | 2011-09-28 |
Family
ID=42276241
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020080109116A KR101068128B1 (en) | 2008-11-04 | 2008-11-04 | Natural product composition containing ionized calcium fertilized unmilled rice for activating alcohol excretion,aldehyde metabolism and curing a hangover and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101068128B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210085011A (en) | 2019-12-30 | 2021-07-08 | 종근당건강 주식회사 | Composition for relieving hangover comprising matured silkworm and yeast extract as an active ingredient |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101882791B1 (en) * | 2017-12-26 | 2018-07-30 | (주)메디언스 | Food composition containing the extract of Zea mays L. with anthocyanin for healing a hangover |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR930012028A (en) * | 1991-12-19 | 1993-07-20 | 박용성 | Herbal Medicine |
KR100357418B1 (en) | 2000-03-17 | 2002-10-18 | 대일광업 주식회사 | Freeze Drinking Mixture Beverage Which Contains Nephrite Jade Power And Process For Preparing Thereof |
KR100813338B1 (en) | 2006-06-19 | 2008-03-12 | 최석용 | A method of anti-hangover functional beverage that the dropwort for main ingredient |
KR20090078662A (en) * | 2008-01-15 | 2009-07-20 | 우명순 | Calcium compound containing natural product composition for curing a hangover and preparation method thereof |
-
2008
- 2008-11-04 KR KR1020080109116A patent/KR101068128B1/en active IP Right Grant
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR930012028A (en) * | 1991-12-19 | 1993-07-20 | 박용성 | Herbal Medicine |
KR100357418B1 (en) | 2000-03-17 | 2002-10-18 | 대일광업 주식회사 | Freeze Drinking Mixture Beverage Which Contains Nephrite Jade Power And Process For Preparing Thereof |
KR100813338B1 (en) | 2006-06-19 | 2008-03-12 | 최석용 | A method of anti-hangover functional beverage that the dropwort for main ingredient |
KR20090078662A (en) * | 2008-01-15 | 2009-07-20 | 우명순 | Calcium compound containing natural product composition for curing a hangover and preparation method thereof |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210085011A (en) | 2019-12-30 | 2021-07-08 | 종근당건강 주식회사 | Composition for relieving hangover comprising matured silkworm and yeast extract as an active ingredient |
Also Published As
Publication number | Publication date |
---|---|
KR20100050032A (en) | 2010-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100968109B1 (en) | Calcium?compound containing natural product composition for curing a hangover and preparation method thereof | |
KR101176590B1 (en) | Herbal Composition for Removing Hangover and Beverage Containing the Same | |
KR101090284B1 (en) | Tonic comprising red ginseng and deer antlers extracts and manufacturing method thereof | |
CN105380051B (en) | A kind of anti-alcohol and liver-protection beverage and preparation method thereof | |
KR20180037693A (en) | A food composition for preventing and improving lung diseases | |
KR20020041639A (en) | Compositions effective for removing hangover which contains natural herb tea extracts and health supplementing foods containing the same as an effective ingredient | |
CN105695258A (en) | Female health wine containing lychee seed saponin | |
CN103168883A (en) | Pathogenic microorganism preventing antiviral tea beverage granules capable of boosting immunity and preparation method thereof | |
CN109730180A (en) | A kind of lowering blood pressure and blood fat, hypoglycemic composition and preparation method thereof and tea bag | |
CN105454576A (en) | Jasmine-flower-comprising assorted Chinese herbal tea and preparation method thereof | |
KR101632794B1 (en) | METHOD OF MANUFACTURING PILL COMPRISED OF Protaetia brevitarsis seulensis | |
KR100552398B1 (en) | An alcohol detoxification beverage comprising extract of horse bean | |
CN103610803A (en) | Traditional Chinese medicine composition for protecting liver and dispelling effects of alcohol | |
CN108813501B (en) | Health-preserving honey paste with functions of clearing heat, moistening lung, relieving cough, reducing phlegm, relieving asthma and regulating human body functions | |
KR20090127970A (en) | Uncooked food pill and its manufacturing process | |
KR100891914B1 (en) | The method of preparing the functional food for diet using extrative extrated from madicin-matrrials of plants | |
KR20070005317A (en) | Health supporting food for a diabetic with a jerusalem artichoke as main material | |
KR101195109B1 (en) | composition of health food | |
CN104873826A (en) | Tea drink capable of clearing away lung heat and dispelling damp and preparation method thereof | |
KR101224196B1 (en) | Method for omega-3 of crude drug and containing extracts hippophae rhamnoides l. | |
KR101068128B1 (en) | Natural product composition containing ionized calcium fertilized unmilled rice for activating alcohol excretion,aldehyde metabolism and curing a hangover and preparation method thereof | |
KR100406158B1 (en) | The human body a poisonous toxic substance eliminate waste matter from the system natural product a manufacturing process | |
KR100638491B1 (en) | Compounds for relief of alcoholic hangover and drug containing the compounds | |
CN108419869A (en) | Fiery composition, beverage and preparation method thereof under a kind of heat-clearing toxin expelling | |
KR102136053B1 (en) | Composition for Removing Hangover Comprising Herb Extract and Beverage Thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
N231 | Notification of change of applicant | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20140820 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20150827 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20160829 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20180903 Year of fee payment: 8 |